Clinical Investigation  Plan – ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 1 of 84 Document Number 950057, Rev. E 25-MAR -2017 
 
 
  
Clinical Investigation Plan 
(ReActiv8-B)  
 
A Clinical Trial under an Investigational Device Exemption (IDE)  
 
ReActiv8 Implantable Neuros timulation System  
for Chronic Low Back Pain  
 
Sponsor  
MML US Inc.  
6601 Shingle Creek Parkway  
Brooklyn Center, MN 554 30 
Document Number 950057, Rev. E  
25-MAR -2017  
[STUDY_ID_REMOVED]  
 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 2 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Revision History 
Rev Change Description  Effective 
Date  
A Initial Release  to production 27-Aug-2015  
B Exclusion Criteria:  
• Minor c larification to the wording for financial gain 
exclusion 
• Removed the compliance exclusion for the pain 
diary  
Updated Product modifications and product additions  
Updated Statistically section to match updated SAP  which 
includes details on the interim analysis as requested from the 
FDA 
Modified the m edication collection of rescue medications  for 
other pain conditions  as recommended by the FDA  
Table 5 Study Completion plan updated on availability of  
product use after study  
Clarification that the telephone call prior to visits could also be 
done electronically  
Clarification that the trainers for the PIT will follow a plan for 
training and PIT training materials will be developed by the 
qualified trainers and used consistently at each site  
Minor typographical errors and inconsistencies  corrected 
throughout document  10-Dec-2015  
C Exclusion Criteria:  
• Minor clarification to the wording for pathology seen on 
MRI (see Eligibility Criteria in Table 1 and s ections 5.2 and 
10.1.3).  
• Minor clarification to the wording for prior diagnosis  of 
lumbar vertebral compression (see Eligibility Criteria in 
Table 1 and section 5.2).  
Timing of implant visit from baseline revised from 30 days to  
45 days to allow sufficient time for diagnostic tests  and 
independent MRI assessment  to be completed and surgery 
scheduled (see Study Schedule in Table 1 and section 6.2 ). 
Clarified that the Percent Pain Relief (PPR) metric is obtained  
by a question asked to the Subject by  the Investigator or 
Coordinator (and not via a questionnaire) . See section 4.6.4.  05-Sep-2016  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 3 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Sponsor address change and overall study princi pal 
investigator address change (see section 11) . 
Minor typographical errors and inconsistencies corrected 
throughout document . 
D Removed the Upper Limit for age of subjects in the Trial.  
 
Revised to reflect the requirement for a Psychological 
Assessment for every subject prior to inclusion in the Trial.  
 
Revised to clarify that an Informed consent may be signed by 
an Investigator OR the investigator's delegate.  
 
Added a statement that the Study PI conducts a final review 
for all subjects to ensure inclusion/exclusion requirements are 
satisfied.  
 
Added the ReActiv8 Lead Models 8145/ 8165 to the ReActiv8 
Product Family.  31-JAN-2017  
E Updated age limit for subjects in the Trial to ≤ 75 years old.  25-MAR -2017  
 
 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 4 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Investigator Signature Page  
Investigator Acknowledgement Signature:  
 
I have received and reviewed this Clinical Investigational Plan. I will conduct the T rial as 
described.  
 
_________________________________ ___________  
Investigator’s Name (print)  Site Number  
 
 
_________________________________ ___________ 
Investigator’s S ignature  Date  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 5 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Table of Contents  
1. Study Purpose  ........................................................................................................ 9 
2. Overview  ................................................................................................................. 9 
2.1. Chronic Low Back Pain ................................................................................................... 9 
2.2. ReActiv8  ........................................................................................................................  10 
2.3. Discussio n on Outcome Measures  ................................................................................ 11 
2.4. Overall Synopsis of the Clinical Investigation.................................................................  12 
3. The ReActiv8 Therapy .......................................................................................... 21 
3.1. Summary of ReActiv8  .................................................................................................... 21 
3.2. Surgical Implantation and Device Activation .................................................................. 22 
3.3. Physician Training ......................................................................................................... 23 
4. Study Design  ......................................................................................................... 24 
4.1. Hypothesis  .................................................................................................................... 24 
4.2. Proposed Indications for Use for ReActiv8  .................................................................... 24 
4.3. Study Population  ........................................................................................................... 24 
4.4. Study Size and Duration ................................................................................................ 24 
4.4.1.  Investigational Sites  ....................................................................................................... 24 
4.4.2.  Surgical Roll In Phase  ................................................................................................... 25 
4.4.3.  Study Duration  ............................................................................................................... 25 
4.5. Assessment of Lumbar Multifidus Dysfunction ............................................................... 25 
4.6. Outcome Measures  ....................................................................................................... 26 
4.6.1.  Low Back Pain Visual Analog Scale (VAS)  ................................................................... 26 
4.6.2.  ODI .................................................................................................................................  27 
4.6.3.  EQ-5D ............................................................................................................................ 27 
4.6.4.  Percent P ain Relief (PPR)  ............................................................................................. 28 
4.6.5.  SGIC  .............................................................................................................................. 28 
4.6.6.  Clinical Global Impression  ............................................................................................. 28 
4.6.7.  Resolution of Back Pain  .................................................................................................  28 
4.7. Clinical Trial Endpoints  .................................................................................................. 29 
4.7.1.  Primary Endpoint – Low Back Pain VAS  ....................................................................... 29 
4.7.2.  Secondary Efficacy Endpoints  ....................................................................................... 30 
4.7.3.  Primary Safety Assessment  ........................................................................................... 31 
4.7.4.  Supporting Safety Analysis  ............................................................................................ 31 
4.7.5.  Supporting Analyses  ...................................................................................................... 31 
4.7.6.  Health Economics  .......................................................................................................... 32 
4.8. Control Arm  ................................................................................................................... 33 
4.9. Blinding and Blinding Assessment  ................................................................................. 34 
4.10.  Crossover  ...................................................................................................................... 35 
4.11.  Data C ollection  .............................................................................................................. 35 
4.12.  Stimulation Compliance .................................................................................................  35 
4.13.  Statistical Plan  ............................................................................................................... 36 
4.14.  Trial Schema  ................................................................................................................. 37 
5. Subject  Selection and Withdrawal  ...................................................................... 39 
5.1. Inclusion Criteria  ............................................................................................................ 39 
5.2. Exclusion Criteria  .......................................................................................................... 39 
5.3. Other Therapy During the Trial  ...................................................................................... 42 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 6 of 84 Document Number 950057, Rev. E 25-MAR -2017 
5.3.1.  Medication  ...................................................................................................................... 42 
5.3.2.  Physiotherapy & Exercise  .............................................................................................. 43 
5.3.3.  Other Devices or Therapy  .............................................................................................. 43 
6. Subject Contact and Data Collection Schedule  ................................................. 44 
6.1. Visit 1: Informed Consent, Baseline Data, Inclusion Decision ........................................ 44 
6.2. Visit 2: Implant Procedure................................................................ .............................. 45 
6.3. Visit 3: Post -Implant 7 - 0+10 Days  ................................................................................ 46 
6.4. Visit 4: Randomization & Activation Visit 14 ±  3 days Post Implant  ................................ 46 
6.5. Visit 5: 14±7 Days Post Randomization ......................................................................... 47 
6.6. Visit 6: 45±7 Days Post Randomization ......................................................................... 47 
6.7. Visit 7: 75±10 Days Post Randomization  ....................................................................... 48 
6.8. Visit 8: 120 - 0/+20 Days Post Randomization  ................................................................ 49 
6.9. Visit 8a: Crossover and Activation  ................................................................................. 49 
6.10.  Visit 9: 180 ± 30 Days Post Randomization  ................................................................... 50 
6.11.  Visits 10: 240 ± 30 Days Post Randomization  ............................................................... 50 
6.12.  Visits 11: 12 Months 0 -30/+60 Days Post Randomization  .............................................. 51 
6.13.  Annual Follow Up .......................................................................................................... 51 
6.14.  Unscheduled Visits  ........................................................................................................ 52 
6.15.  Telephone Calls or Electronic contact  ........................................................................... 52 
6.16.  Revision/Explant Procedure  .......................................................................................... 53 
7. Anticipated Benefits and Risks  ........................................................................... 54 
7.1. Anticipated Benefits  ....................................................................................................... 54 
7.2. Anticipated Risks  ........................................................................................................... 54 
7.3. Risk Minimization  .......................................................................................................... 56 
8. Safety ..................................................................................................................... 57 
8.1. Adverse Event Reporting  ............................................................................................... 58 
8.2. Adverse Event Outcome Status  ..................................................................................... 59 
8.3. Device Deficiencies  ....................................................................................................... 59 
8.4. Subject Deaths  .............................................................................................................. 59 
9. Data Management  .................................................................................................  61 
9.1. Study Assessments  ....................................................................................................... 61 
9.1.1.  Medical History  .............................................................................................................. 61 
9.1.2.  Subject Screening/Baseline  ........................................................................................... 61 
9.1.3.  Depression Anxiety Stress Scale (DASS 21) ................................................................... 62 
9.1.4.  Surgical Procedure  ........................................................................................................ 62 
9.1.5. Post-Operative Evaluation  ............................................................................................. 62 
9.1.6.  Physical Exam and Surgical Site Exam (Post Implant)  ................................................. 62 
9.1.7.  Oswestry Disability Index  ............................................................................................... 62 
9.1.8.  Low Back Pain VAS  ....................................................................................................... 62 
9.1.9.  Medication  ...................................................................................................................... 63 
9.1.10.  Treatment Satisfaction Questionnaire  ........................................................................... 63 
9.1.11. Subject Global Impression of Change  ........................................................................... 63 
9.1.12.  Clinical Global Impression – Global Improvement ......................................................... 63 
9.1.13.  EQ-5D ............................................................................................................................ 64 
9.1.14.  Adverse Events  .............................................................................................................. 64 
9.1.15.  Device Deficiency  .......................................................................................................... 64 
9.2. Management of Protocol Deviations  .............................................................................. 64 
9.3. Informed Consent  .......................................................................................................... 65 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 7 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9.4. Subject Classification  .................................................................................................... 65 
9.5. Subject Data Confidentiality  ........................................................................................... 65 
9.6. Record Keeping  ............................................................................................................. 66 
10. Study Management  ............................................................................................... 68 
10.1.  Committees and Independent Review  ........................................................................... 68 
10.1.1.  Data Monitoring Committee  ........................................................................................... 68 
10.1.2.  Adjudication Committee  .................................................................................................  68 
10.1.3.  Independent Assessment of Surgical Candidacy  .......................................................... 68 
10.2.  Study Principal Investigator Review  ............................................................................... 68 
10.3.  Procedures to Amend th e Clinical Investigation Plan ..................................................... 68 
10.4.  Device Accountability  .................................................................................................... 69 
10.5.  Labeling  ......................................................................................................................... 69 
10.6.  Data Monitoring Plan  ..................................................................................................... 70 
10.7.  Sponsor Responsibilities  ............................................................................................... 70 
10.8.  Role of the Sponsor Representatives  ............................................................................ 71 
10.9.  Clinical Investigators  ...................................................................................................... 71 
10.10.  Investigator Selection  .................................................................................................... 72 
10.11.  Publication Policy  .......................................................................................................... 73 
10.12.  Payment of Subjects  ...................................................................................................... 73 
10.13.  Maintaining Compliance  ................................................................................................ 73 
10.13.1.  Study Monitoring  ............................................................................................................ 73 
10.13.2.  Review of Submitted Data  ............................................................................................. 74 
10.13.3.  Securing Compliance  ..................................................................................................... 74 
10.14.  Study Completion .......................................................................................................... 74 
10.15.  Suspension or Premature Termination of the Trial  ......................................................... 74 
11. Administrative Data  .............................................................................................. 77 
11.1.  Name and Address of the Sponsor  ................................................................................ 77 
11.2.  Investigators  .................................................................................................................. 77 
11.3.  Data Monitoring Committee ........................................................................................... 77 
11.4.  Adjudication Committee  .................................................................................................  77 
11.5.  Clinical Research Organizations (CROs)  ....................................................................... 78 
11.6.  Statements of Compliance ............................................................................................. 78 
Appendix 1: Acronyms and Definitions  .................................................................... 79 
Appendix 2: Bibliography  ........................................................................................... 82 
Table of Figures  
Figure 1: Conducting the Prone Instability Test  .........................................................................26 
Figure 2: Subject Global Impression of Change (SGIC) Questionnaire  .....................................28 
Figure 3: Clinical Global Impression Questionnaire ................................................................... 28 
Figure 4: Blinding Assessment Questionnaire  ...........................................................................35 
Figure 5: Trial Schema  ..............................................................................................................37 
Figure 6: Treatment Satisfaction Questionnaire  ........................................................................63 
Table of Tables  
Table 1: Synopsis of Clinical Investigation ................................................................................13 
Table 2: Summary Data Collection Schedule ............................................................................38 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 8 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Table 3: Benzodiazepine Equivalents  .......................................................................................42 
Table 4: Adverse Event Relatedness Categories  ......................................................................57 
Table 5: Study Completion Plan ................................................................................................76 
 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 9 of 84 Document Number 950057, Rev. E 25-MAR -2017 
1. Study Purpose  
To evaluate the safety and efficacy of ReActiv8 for the treatment of adults with Chronic Low 
Back Pain and no prior surgery when used in conjunction with medical management.  
2. Overview  
MML US Inc. (the Sponsor) is a wholly owned subsidiary of Mainstay Medical Limited (based in 
Ireland (“Mainstay”). Mainstay has developed an implantable medical devi ce designed as 
therapy for people with chronic low back pain (CLBP). The device, called ReActiv8®, consists of 
two implantable leads with four electrodes each, configured to deliver bilateral electrical 
stimulation to the medial branch of the dorsal ramus nerves as they cross the transverse 
process at L3 to elicit bilateral contraction of the lumbar multifidus muscles ( LM). The leads are 
coupled to a  battery powered implantable pulse generator (IPG) which is activated by an 
external Activator, and is programmed via a programmer. Several accessories are included as 
part of the system, for example to facilitate the surgical procedure.  
The therapy delivered by the ReActiv8 was explored with a European Feasibility Study in 2011 
to 2013 using “off the shelf ” general purpose neurostimulation devi ces from other 
manufacturers, and results have been published.1 A report of that Study is included in the 
Report of P rior Investigations . 
ReActiv8 is being investigated under an ongoing clinical trial to generate data for a submission 
for CE Mark approval in Europe. Subjects are enrolled at several sites in Australia and Europe. 
Details of this trial can be found at http://clinicaltrials.gov/show/[STUDY_ID_REMOVED]  and the interim 
results of the ReActiv8- A clinical investigation are included in the Report of Prior Investigations 
and the Investigators Brochure.   
2.1. Chronic L ow Back Pain  
This section is a summary of the scienti fic background of the ReActiv8.  
Low back pain is usually defined as pain and discomfort, localized below the costal margin and 
above the inferior gluteal fold, with or without referred leg pain.2,3 Chronic Low Back Pain 
(CLBP) is usually defined as back pain for at least 3 months. The NIH Task Force on Research 
Standards for Chronic Lo w Back Pain recommended4 that Chronic Low Back Pain be defined as 
a back pain probl em that has persisted for at least 3 months and has resulted in pain on at least 
half the days in the past 6 months.  
Chronic low back pain is a major health problem, and the World Health Organization reports that 
“Low back pain is the most prevalent of mus culoskeletal conditions; it affects nearly everyone at 
some point in time and about 4– 33% of the population at any given point”5 and back pain is the 
number one cause of years lived with disability worldwide in 2013.6 There are many publications 
on the epidemiology7 of back pain including prevalence,8,9,10 natural history, demographics, and 
country by country variability.  
People with acute low back pain and associated disability usually improve rapidly within weeks, 
but pain and disability typically continue, and recurrences are common.11 Although most 
episodes of acute back p ain resolve within 3 months, “recovery after 12 weeks is slow and 
uncertain. Fewer than half of those individuals disabled for longer than 6 months return to work 
and, after 2 years of absence from work, the return- to-work rate is close to zero.”12 Like many 
chronic conditions, the costs are driven by the small proportion of the population who have been 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 10 of 84 Document Number 950057, Rev. E 25-MAR -2017 
sick f or the longest period – for back pain, patients with disability >1 year account for 5% of 
cases, but 65% of costs .13,14 
Although there has been a lot of attention and investment applied to surgical treatments for low 
back pain, only approximately 20% of patients are suitable surgical candidates.15 The remaining 
patients are sometimes referred to as having “non -specific low back pain” (NSLBP) or “axial low 
back pain” (ALBP). There are European clinical practice guidelines for chronic NSLBP2 and UK 
guidelines for management of patients with persistent CLBP (published by the National Institu te 
for Clinical Excellence -  NICE) .16 US guidelines for acute and chronic low back pain are similar 
to the European guidelines .17 
Exercise therapy is frequently prescribed for NSLBP, but the effectiveness of exercise therapy 
for acute  back pain is negligible.18 Systematic reviews of the literature19,20 concerning therapies 
for chronic  low back pain show that exercise is generally ineffective, other than certain types of 
exercise therapy which can be effective in a small subset  of patients.  
Many non -invasive conservative therapies have been tried with modest or no success, and 
several revi ews are available.21 Therapies include lumbar extensor strengthening exercises ;22 
watchful waiting (i.e. , no therapy) ,23 traction therapy ,24 the McKenzie Method of exerc ise 
therapy ,25 various types of energy applicat ion including ultrasound, TENS ,26 osteopathic 
therapy,27 and thermotherapy ,28 and lumbar stabilization exercises.29 
Following failure of conservative therapy for CLBP, “ usual care” or “conventional medical 
management” for CLBP usually consists of coping mechanisms for pain, and pain medications 
(often opioids), which are often increased during the episodic flare- ups of pain.  
2.2. ReActiv8  
Arthrogenic muscle inhibition (AMI)30 is the physiological mechanism by which pain in a skeletal 
joint disrupts the motor control to the muscles that stabilize the joint – often observed in the 
quadriceps post knee surgery. A similar mechanism underlies some types of chronic low back 
pain, with disruption to the motor control of the key stabilizing muscles –  the lumbar multifidus . 
Evidence includes diminished EMG a ctivity in back pain patients31 and delayed reflex response 
of the LM to perturbations.32 Pain alters the magnitude of activation of deep LM  during certain 
types of activ ity.33 Ultrasound imaging evidence of reduced neural drive in back pain patients 
includes diminished cross sectional area with contraction,34 reduced ability to cause a muscle 
thickness change on command ,35 and altered contraction patterns with changes in posture.36 
Published studies show that subject initiated contraction of the lumbar multifidus with ultrasound 
guided biofeedback motor control physical therapy exercises can lead to improvement s in back 
pain, but this approach has not been adopted due to practical challenges, economic difficulties, 
and patient compliance issues. The mechanism of action is believed to be restoration of motor 
control of the lumbar multifidus, thereby leading to rehabilitation of the muscle, improved spine 
stability and reduction in back pain.  
Electrical stimulation to restore motor control has been successfully used with other skeletal 
muscles. In particular , stimulation via superficial (skin) electrodes over the m otor point of the 
quadriceps can restore neural drive and allow rehabilitation of the muscle in patients following 
total knee arthroplasty37 or other surgical procedures.38,39 Painful knee osteoarthritis can be 
treated without surgery but may also lead to pain mediated inhibition of neural drive to the 
quadriceps, which can be treated effectively with electrical  stimulation.40  
The ReAct iv8 has been designed to incorporate the principles of these prior approaches . 
Bilateral e lectrical stimulation of the medial branch of the dorsal ramus nerve that innervates the 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 11 of 84 Document Number 950057, Rev. E 25-MAR -2017 
lumbar multifidus is delivered episodically  (10 seconds “ on” followed by  20 seconds “ off”, for 30 
minutes, during two sessions  per day) . Previous experience with the therapy in the European 
Feasibility Study showed that many  subjects can perceiv e the muscle contractions, and report 
the muscle contractions  as “soothing” or “pleasurable.”  
The intent to implant leads bilaterally and give bilateral stimulation is based on published 
research that indicates that multifidus dysfunction (atrophy) is likely to be bilateral even if the 
patient reports unilateral pain.  
Beneck showed41 that in people with chronic unilat eral low back pain (<1 year) multifidus 
atrophy  is bilateral with no difference in multifidus volume between the painful and non -painful 
sides.  
D’Hooge explored changes in muscle fiber type of the multifidus erector spinae, quadratus 
lumborum and psoas using MRI imaging42 and sh owed a conversion of (only) multifidus muscle 
fiber type towards the glycolytic (anaerobic) muscle spectrum bilaterally in patients with 
unilateral low back pain, and the changes persist after resolution of the pain.  
Dickx showed43 in an experimental human model that using hypertonic saline to induce 
unilateral pain at one segmental level resulted in bilateral dysfunction of th e multifidus muscle 
and at multiple segmental levels.  
Furthermore, the incremental risk of bilateral stimulation over unilateral stimulation is judged to 
be low –  as the primary risk is associated with the surgical procedure itself and the incremental 
time for placement of the second lead is approximately 15 minutes. Conversely, implantation of 
one lead only (unilateral stimulation) exposes the subject to the risk of an additional surgical 
procedure if it is found that a second lead is needed for bilateral stimulation. Therefore,  bilateral 
treatment is preferred over unilateral treatment.  
2.3. Discussion on Outcome Measures  
Since the primary indication for ReActiv8 is to provide pain relief, the primary endpoint is based 
on a valid outcome measure for pain.  
Many outcome measures have been used in clinical trials for pain, and specifically for low back 
pain, and more specifically for chronic low back pain.  There are multiple recommendations from 
the IMMPACT group (Initiative on Methods, Measurement, and Pain Assess ment in Clinical 
Trials)44,45,46 which are generalizable to many trials for treatment of pain. T he Visual Analog 
Scale (VAS) or the Numerical Rating Scale (NRS) are well accepted measures of pain. VAS is a 
widely used outcome measure in assessing pain due to the documented reliability, ease in 
administration and the minimal training requirements to administer the VAS tool.47 
For this Trial, the primary endpoint is a comparison of responder rates  between Treatment and 
Control groups,  where a “responder ” is a subject with ≥ 30% reduction from baseline in average  
low back pain VAS recalled for the previous 7 days , without any increase from baseline in pain 
medication and/or muscle relaxants (pain medications) prescribed and taken in the two weeks 
prior to the Primary Endpoint A ssessment Visit. 
Oswestry Disability Index (ODI) is a disease specific assessment of the disabling effects of back 
pain.48 The ODI covers 1 item on pain and 9 items on activities of daily living (personal care, 
lifting, walking, sitting, standing, sleeping, s ex life, social life, and traveling). ODI is reported as a 
score from 0 to 100%. Recent  CLBP studies use a disability index as the primary outcome 
measure rather than pain.49,50 In this T rial ODI is an important secondary endpoint.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 12 of 84 Document Number 950057, Rev. E 25-MAR -2017 
2.4. Overall S ynopsis of the Clinical Investigation  
The Clinical Investigation is an international, multi -center, prospective, randomized, sham 
controlled, blinded T rial with an adaptive statistical design. The Trial is powered for statistical 
significance and the Statistical Analysis  Plan is provided in a separate document and 
summarized herein. A synopsis in tabular form is shown in Table 1. 
All Subjectsa who satisfy the baseline criteria are implanted with the ReActiv8, and then at the 
Randomization Visit are instructed to deliver stimulation during two 30- minute sessions 
(morning and evening)  per day . Subjec ts are randomized (1:1) to the Treatment or Control Arm 
at the Randomization Visit. 
Subjects randomized to the T reatment Arm of the study will have ReActiv8 programm ed to 
deliver stimulation at a S ubject -appropriate level (t he Treatment  group). Determination of the 
Subject  appropriate level is described in the Implant and Programming Manual. Subjects in the 
Treatment group  may or may not feel sensations  during stimulation.  
Subjects randomized to the C ontrol Arm will have ReActiv8 programmed t o deliver minimal 
stimulation (t he Control  group).  Subjects in the Control group may or may not feel sensations  
during stimulation.  
All subjects will have automatic electrical impedance measurement of electrodes performed 
immediately prior to each stimulation session.  
Thus , with this design, all subjects receive some electrical stimul ation. The Informed Consent 
will advise subjects that electrical stimulation will be delivered, and subjects may or may not feel 
something associated with the stimulation.  Subjects  will also be advised in the Informed 
Consent that they will be randomized to one of two different treatment regimes.  
Subjects will be eligible for enrollment  if they have chronic low back pain that has persisted > 90 
days that has resulted in pain in at least half of the days in the 12 months prior to the Baseline 
Visit, despite medical management including at least pain medications and one attempt of a 
prescribed physical therapy program  for low back pain, and satisfy the othe r eligibility criteria. It 
is likely that subjects will have tried and failed other conservative treatment options including 
one or more of chiropractic, massage, cognitive behavioral therapy, medial branch rhizotomy, 
nerve blocks, steroid injections, acupuncture or lumbar supports. All treatments that have been 
tried will be recorded.  
All endpoints are assessed at 120 days post randomiz ation (at the Primary Endpoint 
Assessment Visit ). 
Compliance with instructions for  stimulation delivery will be assessed f rom data stored in the 
ReActiv8 IPG, which records the start and stop time of each stimulation session.  
The Primary Efficacy E ndpoint is a comparison of responder rates of pain where a “responder” 
is a Subject with ≥30% reduction from baseline in average l ow back pain VAS, without any 
increase in pain medication and/or muscle relaxants prescribed and taken in the two weeks 
prior to the Primary Endpoint A ssessment Visit. 
Several secondary endpoints  will be assessed, including change in ODI, change in EQ -5D 
Quality of Life, change in Percent Pain Relief , and Subject Global Impression of Change, all 
assessed as a difference between baseline and the Primary Endpoint Assessment Visit . 
 
a  In this Clinical Investigation Plan, the term used is “subject” instead of “patient” in line with the suggestions of ISO  14155 . 
The terms should be considered as synonymous.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 13 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Subgroups will be also analyz ed based on Subject  characteristics (e.g.: BMI) and by site. 
Several other endpoints will be analyz ed on an exploratory basis.  
Safety will be assessed by  collecting data on  the rate of all serious device and/or procedure 
related adverse events in all enrolled Subjects . Adverse event data will be collected at each visit 
beginning with the Baseline Visit. The Safety Cohort consists of all enrolled S ubjects in whom 
implant was attempted or successful.  A separate analysis will be conducted of the Safety Cohort 
without Subjects included in the Surgical Roll In Cohort.  
Table 1: Synopsis of Clinical Investigation 
Study Purpose  To evaluate the safety and efficacy of  ReActiv8 for the treatment of adults 
with Chronic Low Back  Pain and no prior spine surgery when used in 
conjunction with medical m anagement.  
Indication For 
Use ReActiv8 is an adjunct  to medical management in adults with  Chronic Low 
Back Pain  for relief of  pain in subjects who have failed at least medical 
management and physical therapy . 
Study Device  Mainstay ReActiv8  
Study Design  International, multi -center, prospective, randomized, sham controlled, blinded 
Trial with an adaptive statistical design. Sub jects are blinded, investigators 
are blinded, and the assessment of primary endpoint data is blinded.  
Treatment  Arm ReActiv8 implanted and configured to deliver stimulation at a Subject -
appropriate level and Subjects instructed to deliver stimulation  in two 
30-minute sessions  per day  (the Treatment  group) . 
Control Arm  ReActiv8 implanted and configured to deliver minimal stimulation , and 
Subjects instructed t o deliver stimulation in two 30- minute sessi ons per day  
(the Control  group).  
Randomization Subjects meeting all eligibility criteria who have been implanted with ReActiv8 
will be randomized post -implant  to either the Treatment group or the Control 
group. Randomization will be performed according to a random permuted 
block design st ratified by clinical site with a 1:1 allocation ratio for Treatment 
vs. Control.  
Anticipated 
Sample Size Initial estimate: 128  randomized Subjects  implanted with ReActiv8 in the 
intent to T reat cohort  of the study , plus up to  80 Subjects  implanted in the 
Surgical Roll In group.  
An adaptive statistical design using a single interim look will be used for 
sample size re- estimation  when at least 50% of the implanted S ubjects have 
completed the P rimary Endpoint Assessment Visit. 
Up to 800 Subjects will be enrolled to account for  screen failures  prior to 
implant , Surgical Roll In, drop outs, and possible increase in numbers  for the 
intent to treat analyses  after the interim look.  
Anticipated 
Number of Sites  There will be up to 40 Investigati onal sites performing implants . Each site will 
have a Site Principal Investigator who may or may not be the implanting 
physician. One or more Sub -investigators per site (or affiliated site if the 
affiliated site has a different Ethics Committee or IRB) may  be used for 
example for device implantation and Subject  recruitment.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 14 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Surgical 
Training and 
Surgical Roll In  All physicians who will implant any portion of the system will be trained as 
outlined in the Training Strategy . Following training, up to the first two 
Subjects implanted by the same physician may be prospectively included in a 
Surgical Roll In group.  Subjects included in the S urgical Roll In group will be 
randomized to Treatment or Control with a single group randomization, and 
be analyzed as a separate cohort  (the Surgical Roll In Cohort) . 
Crossover and 
Open Label 
Phase Following endpoint assessment at the Primary Endpoint Assessment Visit : 
• Subjects randomized to the Control Arm will have ReActiv8 configured 
to deliver stimulation at a Subject -appropriate level, and S ubjects will 
be instructed to deliver stimulation in two 30- minute sessions  per day . 
Once the Control  group has crossed over, it will be referred to as the 
Crossover group.  
• All Subjects in the Treatment group will be advised to continue to use 
their devices for two 30 -minute sessions per day.  
• All Subjects will be permitted to change their medications  
Primary Efficacy 
Endpoint  The Primary Efficacy Endpoint is a comparison of responder rates  between 
Treatment and Control groups , where a “responder” is a Subject  with ≥30% 
reduction from baseline in  average  low back pain VAS without any increase 
in pain medi cation and/or muscle relaxants prescribed and taken in the two 
weeks prior to the P rimary Endpoint A ssessment Visit. 
Secondary 
Efficacy 
Endpoints  The hypotheses will be tested utilizing an overall Type I error of 5%. The 
overall Type I error will be maintained by utilizing Hochberg’s method to test 
the collection of the first five secondary objectives. These will be tested only if 
the primary efficacy endpoint is met.  
1. Comparison of change from baseline in ODI between Treatment and 
Control groups at the Primary Endp oint Assessment Visit  
2. Comparison of change from baseline in EQ -5D between Treatment and 
Control groups at the Primary Endp oint Assessment Visit  
3. Comparison of Percent Pain Relief between Treatment and Control 
groups reported by the Subject  at the Primary Endp oint Assessment Visit  
4. Comparison of Subject Global Impression of Change at the Primary 
Endpoint Assessment Visit  
5. Comparison of number of S ubjects with Resolution of Low Back Pain 
(remitters or cure , defined as a VAS score ≤ 2.5cm ) at the Primary 
Endpoint Assessment Visit  
6. Evaluation of changes in primary and secondary efficacy metrics in 
Cross over Group following the Outcome Post Crossover V isit. 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 15 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Supporting 
Analyses  The Supporting Analyses will include:  
• Once data are complete, all primary and secondary outcome measures 
will be assessed at 12 months and compared to baseline within the 
Treatment  group . The  analysis will also explore correlation of outcomes  
to amount of  stimulation delivered.  
• In the Crossover Group, outcome measures will be assessed at the 
Outcome Post Crossover Visit for all S ubjects who met the inclusion 
criteria for low back pain at the Primary Endpoint Assessment Visit (i.e.: 
prior to Crossover) ( Average Low Back Pain VAS of ≥6.0cm  and ≤9.0 cm 
on a VAS scale (0 -10cm )) and inclusion criterion for ODI (Oswestry 
Disability Index score ≥2 1% and ≤ 60%). The analysis will also explore 
correlation of outcomes to amount of stimulation delivered.  
• Comparison of daily average VAS averaged over the prior 7 days of 
Journal entry with the single point VAS of recollection of prior 7 days of 
daily average pain.  
• Comparison of EQ -5D VAS between Treatment  and Control  groups at 
each visit at which EQ -5D is recorded through 12 months.  
• For both the Treatment and Control g roups , a cumulative proportion of 
responder analysis51 for both ODI and reduction in back pain ( VAS) so 
that the entire distribution of treatment response is depicted in a graph of 
the proportion of responders for all percentages from 0% to 100% . 
• Subject Global Impression of Change at 12 months.  The analysis will also 
explore correlation of outcomes to am ount of stimulation delivered.  
• Treatment Satisfaction Questionnaire at 12 months.  The analysis will also 
explore correlation of outcomes to amount of stimulation delivered.  
• Clinical Global Impression –  Global Improvement (clinician assessment) 
at 12 months . The analysis will also explore correlation of outcomes to 
amount of stimulation delivered.  
• Change in opioids used for treatment of low back pain from baseline to 12 
months . The analysis will also explore correlation of outcomes to amount 
of stimulation delivered . 
Additional ly, ad hoc exploratory analyses may also be conducted.  
Note: Supporting analyses may be incomplete at the time of PMA 
submission.  
Primary Safety 
Assessment  The primary safety assessment  is serious device and/or procedure related 
adverse event s in all Subjects in the Intent to Treat Cohort at the P rimary 
Endpoint Assessment visit . 
Supporting 
Safety Analysis  The PMA Submission will include 12 month safety data on all Subjects 
implanted with ReActiv8 including all S ubjects implanted in the ReActiv8 -B 
Trial for whom 12 month safety data are available, and other persons 
implanted with ReActiv8 in other clinical trials (including the ReActiv8- A 
PMCF Study ) and all post -mark eting registries that are registered on 
www.clinicaltrials.gov . 
A separate safety assessment will be performed on the Surgical Roll In 
group, including a poolability analysis.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 16 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Health 
Economics  Cost-effectiveness of ReActiv8 therapy, extrapolated to the lifetime of the 
device, will be assessed. Key economic outcome measures to be recorded 
will include:  
• Change in work status at all visits.  
• Change in consumption of medications taken for low back pain at all visits 
compared to Baseline.  
• Assessment of health care utilization (office visits, hospital visits, 
emergency room visits, and other therapies such as physical therapy) at 
all visits . 
Note that the Health Economics assessment  is likely to be inco mplete at the 
time of PMA submission for ReActiv8, since not all S ubjects will have 
reached the 12 month point at that time.  
Efficacy Follow 
Up All Subjects will be followed for efficacy until PMA approval  unless the study 
is closed prior to PMA approval for any reason.  
Safety Follow 
Up All Subjects will be followed for safety until PMA approval  or 7 years from the 
Baseline Visit, whichever is longer , unless the study is closed prior to PMA 
approval for any reason . 
Device Data  At each follow up visit during which the ReActiv8 IPG will be interrogated, 
electrical parameters stored in the IPG such as lead impedance will be 
recorded. Results of threshold testing (if performed) and any reprograming 
will be recorded.  
Study Duration  Anticipated to be ≤ 60 months from first Subject  Baseline Visit to PMA 
submission.  
Informed consent for all Subjects will allow for continuing collection of safety 
and efficacy data for a total period of 7  years from the Baseline Visit. 
Study Schedule  • Informed consent , baseline criteria verification,  
• ReActiv8 implant (1 -45 days post inclusion)  
• Post-Implant  Follow -up: 7 days  -0/+10 days post -implant . 
• Randomization and Activation V isit: 14±3 days post -implant   
• 14 day visit: 1 4 ± 7 d ays post-randomization 
• 1.5 month visit: 45  ± 7 days post -randomization 
• 2.5 month visit: 75  ± 10 days post -randomization 
• 4 month visit: 120 -0/+20 days post -randomization - Primary Endpoint 
Assessment  Visit 
• 6 month visit: 180 ± 30 days post -randomization  
• 8 month visit: 240  ± 30 days post -randomization 
• 12 month visit: 360 -30/+ 60 days post -randomization 
• Annual  follow up every 360 ± 60 days post -randomization until Study 
Closure  
For Subjects in the Control group, after the Subject  completes the endpoint 
assessment at the Primary Endpoint Assessment  Visit, the ReActiv8 will be 
programmed to deliver stimulation at a Subject -appropriate level , and other 
activities will be performed.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 17 of 84 Document Number 950057, Rev. E 25-MAR -2017 
The study will be considered complete with regard to  the primary endpoint 
after the required numbers of randomized Subjects have completed the 
Primary End point Assessment Visit . 
Adjunctive 
Therapies  • All medications for treatment of low back pain will be stabilized 30 days 
prior to the Baseline Visit and remain stabilized through the Primary 
Endpoint Assessment Visit . 
• All other treatments for low back pain (e.g. interventional pain treatments, 
chiropractic) will be prohibited until after the Primary End point 
Assessment Visi t. 
Eligibility 
Criteria  Primary In clusion Criteria  
1. Age ≥22  years , ≤75 years  
2. 7 day  recall of average Low Back Pain VAS of ≥6.0cm and ≤9.0cm  (on a 
10cm scale) at the Baseline Visit .  
3. Oswestry Disability Index score ≥21% and ≤60% at the Baseline Visit 
4. Chronic Low Back Pain defined as pain and discomfort localized below 
the costal margin and above the inferior gluteal fold (with or without 
referred leg pain) that has persisted >90 days prior to the Baseline Visit, 
which has resulted in pain in at least half of the days in the 12 months 
prior to the Baseline Visit, as reported by the Subject . 
5. Evidence of lumbar m ultifidus muscle dysfunction by the Prone Instability 
Test (PIT) . 
6. Continuing low back pain despite >90 days of medical management 
including:  
a. At least one attempt of physical therapy treatment for low  back pain , 
which may optionally be accomplished over multiple episodes  or flare -
ups of l ow back pain. 
NOTE  1: Subjects who start a physical therapy program but are 
unable to complete it are still eligible with regards to this inclusion 
criterion . 
NOTE 2: Subjects who participated in a physical therapy program in 
the past since the onset of low back pain but are unwilling or 
unable to participate in a new physical therapy program are still  
eligible with regards to this inclusion criterion ; 
b. For Subjects with m edications  prescribed and used for chronic low 
back pain, usage shall be at a stable dose in the 30 days prior to the 
Baseline Visit as reported by the Subject . 
NOTE 3: A stable dose means  the Subject  reports no significant 
change in regular use of medications, which may include PRN use, 
in the 30 days  prior to  the Baseline Visit. 
7. Be willing and capable of giving Informed Consent.  
8. Ability to comply with the instructions for use and to operate ReActiv8, 
and to comply with this Clinical Investigation Plan.  
9. Suitable for ReActiv8 surgery as determined by the implanting physician 
prior to inclusion.  
Primary Exclusion Criteria  
1. BMI > 35  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 18 of 84 Document Number 950057, Rev. E 25-MAR -2017 
2. Back Pain characteristics:  
a. Any surgical correction procedure for scoliosis at any time, or a current 
clinical diagnosis of moderate  to severe scoliosis  (Cobb angle ≥25°) .52 
b. Lumbar spine stenosis, as defined by an anterior -posterior diameter of 
the spinal canal <10mm in S ubjects with lower extremity pain.  
c. Neurological deficit possibly associated with the back pain (e.g. foot 
drop).  
d. Back pain due to pelvic or visceral reasons (e.g.: endometriosis or 
fibroids) or infection (e.g.: post herpetic neuralgia).  
e. Back pain due to inflammation or damage to the spinal cord or 
adjacent structures (e.g. arachnoiditis or syringomyelia) . 
f. Pathology seen on MRI that is clearly identified and is likely the cause 
of the CLBP  that is amenable to surgery .  
g. Back pain due to vascular causes such as aortic aneurysm  and 
dissection.  
3. An independent assessment of any current indication for back surgery 
according to appropriate  guidelines, or has indications for back surgery 
but cannot undergo surgery for other reasons.  
4. Leg pain described as being worse than back pain, or radiculopathy 
(neuropathic pain) below the knee.  
5. Source of pain is the sacroiliac joint as determined by the Investigator.  
6. Drug use per Subject report as follows:  
a. Current baseline use of >120mg oral morphine equivalent per day of 
opioids.  
b. Current use of breakthrough dose of >60mg oral morphine equivalent 
per day.  
c. Current requirement of  opioids for treatment of a condition other than 
low back pain.  
d. History of any substance abuse at any time in the five years  prior to 
the Baseline Visit. 
e. Currently taking >15mg Diazepam per day or equivalent .  
7. Surgical or other procedures exclusions:  
a. Any previous rhizotomy or rhizolysis procedure, including 
cryoa blation, RF ablation or pulsed RF on the dorsal root ganglion 
(DRG) or the medial branch of the dorsal ramus nerve that crosses or 
lies below the T8 vertebra, within one  year prior to the B aseline Visit. 
b. Anesthetic block of the DRG or medial branch of dors al ramus nerve 
that crosses or lies below the T8 vertebra or injection of epidural 
steroids for back pain in the 30 days prior to the Baseline Visit. 
c. Any previous back surgery including laminectomy or discectomy at or 
below segmental level T8, or spinal fusion at any level . 
d. Any previous thoracic or lumbar sympathectomy . 
8. Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars 
fracture, pars defect, or lumbar annular tear with disc protrusion that is 
amenable to surgery . 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 19 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9. Planned surgery:  
a. Any major surgery (including elective surgery) planned in the twelve 
months following the Baseline Visit (does not include minor surgeries 
not expected to impact the lumbar spine (e.g. colonoscopy) ). 
b. Any elective surgery of any kind (including, for example, tooth 
extraction, gynecological surgery  or cosmetic surgery) in the time 
between the Baseline Visit and the Primary Endpoint Assessment 
Visit. 
10. Any co-morbid chronic pain conditions . 
11. Other clinical conditions:  
a. Pregnant  or planning to be pregnant in the next 12 months, at the time 
of inclusion.  
b. Pregnancy at any time in the 6 months, or lactating at any time in the 
3 months, prior to the Baseline Visit. 
c. Any condition unrelated to the CLBP such as muscle wasting, muscle 
atrophy, other disability (e.g.:  paraplegic, amputee, cerebral palsy ) or 
muscular or skeletal disease (e.g.: arthritis in trunk or limbs, multiple 
sclerosis, rheumatoid arthritis ) which, in the opinion of the Investigator, 
could limit physical movement or compliance with the protocol, or  
interfere with the assessment of efficacy of the investigational 
procedure.  
d. Poorly controlled diabetes (Type I or Type II) determined by HbA1c 
>8. 
e. Past or current neurological disorders (e.g.: known multiple sclerosis, 
motor neuron disease, Guillain- Barré syndrome, Parkinson’s, 
Huntington’s Disease, Alzheimer’s, epilepsy, stroke, brain cancer, 
traumatic brain injury).  
f. Cancer requiring treatment during the study.  
g. Any drugs (e.g.: immunosuppressive drugs) or co -morbidity that might 
inhibit wound healing or electrode scarring, or drugs associated with 
reduced effectiveness of neuromodulation for other applications . 
h. Any medical condition requiring anticoagulation (other than aspirin) 
that, in the opinion of the physician prescribing the anticoagulant, 
cannot be safely suspended for 5 days prior to device implantation 
surgery and an appropriate period after implantation surgery.  
i. Any active infection in the vicinity of the implant site or any systemic 
infection.  
12. Psycho -social exclusions  
a. Be involved in an injury c laim under current litigation.  
b. Have a pending or approved financial compensation claim ( e.g., 
worker’s compensation claim , long term disability claims ) or any 
financial compensation (including social welfare payments) related to 
the Subject’s CLBP.  
c. Current  incarceration (prison or jail)  
d. Have an assessment of current active depression significant enough 
(DASS depression score >953,54) to impact percept ion of pain, 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 20 of 84 Document Number 950057, Rev. E 25-MAR -2017 
compliance with intervention and/or ability to evaluate treatment 
outcome.  
e. Have evidence of an active disruptive psychological or psychiatric 
disorder or other known condition significant enough to impact 
perception of pain, compliance with intervention and/or ability  to 
evaluate treatment outcome (e.g.: active depression, bipolar disease, 
Alzheimer’s disease)  as determined by a psychologist or psychiatrist . 
13. Protocol Compliance Exclusions  
a. Inability or unwillingness to comply with all protocol r equirements.  
b. Inability to maintain the prone or side lying position in a relaxed 
manner for the duration of each stimulation session.  
c. Inability to operate the Activator , such as arthritis that limits arm or 
shoulder movement, or inability to learn how to o perate.  
d. Inability to assess changes in pain intensity or perform wound care.  
e. Inability or unwillingness to complete the Journal.  
14. General exclusions  
a. Any other active implantable device including an implantable device 
for back pain (such as an implantable dr ug pump or Spinal Cord 
Stimulator), pacemaker, implantable defibrillator, cochlear implant, 
deep brain stimulator, or other implanted neurostimulation device.  
b. Prior exposure to an implantable neurostimulator for treatment of pain, 
including spinal cord sti mulation (including trial implant of SCS leads) , 
occipital nerve stimulation or peripheral nerve stimulation.  
c. A condition currently requiring or likely to require use of MRI or 
diathermy while implanted with the ReActiv8 . 
d. Therapy with any other investigati onal intervention (drugs, devices, or 
procedures) for the treatment of back pain at the time of the Baseline 
Visit, or at any time in the past if the past investigational intervention 
did not subsequently gain regulatory approval.  
e. Current or planned participation in any other clinical trial during 
participation in this Trial.  
f. Life expectancy <1 year.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 21 of 84 Document Number 950057, Rev. E 25-MAR -2017 
3. The ReActiv8 Therapy  
3.1. Summary of ReActiv8  
The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an 
implantable pulse generator, leads, programmer, activator and magnet. Refer to the Investigator 
Brochure (IB) or the Implant and Programming Manual  for more detail on device specifications 
and operation.  
Implantable Components of ReActiv8  
The ReActiv8 IPG, and the ReActiv8 leads (available in either 45 cm or 65 cm lengths ), plus 
suture sleeves, are designed for permanent implant.  The implantable components of ReActiv8  
are supplied sterile, and are intended for  single use only.  
• Model 5100 ReActiv8 Implantable Pulse Generator (“IPG”)  
• Model 8000- 45 ReActiv8 Percutaneous  Stimulation Lead, 45 cm  length (“ lead”) 
• Model 8000- 65 ReActiv8 Percutaneous  Stimulation Lead, 65 cm  length (“ lead”) 
• Model 8145 ReActiv8 Percutaneous  Stimulation Lead, 45 cm  length (“ lead”)   
• Model 8165 ReActiv8 Percutaneous  Stimulation Lead, 6 5 cm  length (“ lead”)  
 
Note: The Model 8000- XX and Model 81XX leads are functionally equivalent.  The Model 81XX 
leads incorporate a change to eliminate unused wires within the lead.  
 
Non-Implantable Components of ReActiv8 
The Torque Wrench and Stylet are provided to facilitate implantation of the IPG and leads. The 
Programmer is used to communicate with the IPG in order to program the IPG operational mode 
and settings, read history data  from the IPG , and obtain IPG and lead  status information. The 
Activator is used to initiate and/or suspend stimulation. The Magnet is used to enter Magnet 
Mode (with Magnet Mode operation determined by the programmed parameters of the IPG ). 
• Model 6500/65X0 ReActiv8 Programmer System (“Program mer”) – All Model 65X0 
Programmers contain a Lenovo E420 Laptop computer. Model 6500 contains a 
“universal” set of power cords  (for the UK, US, Belgium and Australia) , while Model 65X0 
contains one power cord that varies by the intended geography for use ( e.g., Model 
6530 contains a US  power cord only) . Mainstay provides the following components of 
the Model 6500/65X0) Programmer in case replacements are needed:  
o Model 6600 Lenovo E420 Laptop (“E420 Laptop”)  
o Model 6700 Medical Grade AC Adapter for the Model 6500/65X0 Programmer  
o Model 6800 Battery for the Model 6600 Lenovo E420 Laptop  
o Model 6000 ReActiv8 Programmer  Wand (“Wand”)  
o Model PP00 Universal Replacement Power Cord Package with AUS, UK, USA 
and Belgian Power Cord  
o Model PP30 USA Replacement Power Cord Package  
• Model 7500/75X0 ReActiv8 Programmer System (“Programmer”) –  All Model 75X0 
Programmers contain a Lenovo E440 laptop computer. Model 7500 contains a 
“universal” set of power cords (for the UK, US, Belgium and Australia), while Model 
75X0 contains one power cord that varies by the intended geography for use (e.g., 
Model 7530 contains a US power cord only).  Additionally, the Model 7500/75X0 
Programmer contains the Model 6750 Medical Grade AC Adapter and the Model 6000 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 22 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Programmer Wand (unchanged from the Model 6500/65X0). Mainstay provides the 
following components of the Model 7500/75X0) Programmer in case replacements are 
needed:  
o Model 7600 Lenovo E440 Laptop (“E440 Laptop”)  
o Model 6750 Medical Grade AC Adapter for the Model 7500/75X0 Programm er 
o Model 7800 Battery for the Model 7600 Lenovo E420 Laptop  
o Model 6000 ReActiv8 Programmer Wand (“Wand”)  
o Model PP00 Universal Replacement Power Cord Package with AUS, UK, USA 
and Belgian Power Cord  
o Model PP30 USA Replacement Power Cord Package  
• Model 7000 ReActiv8 Activator (“Activator”)  
• Model 4000 ReActiv8 Magnet (“Magnet”)  
• Model 5500 ReActiv8 Torque Wrench  – single use - (“Torque Wrench”)  
 Accessories Included with the ReActiv8  
Mainstay supplied accessories included with the ReActiv8 are:  
• Torque Wrench (supplied in the IPG package and also available as a standalone 
accessory)  
• Suture sleeve (optional - supplied in the Lead package)  
• Lead Stylet (supplied in the Lead package)  
• Model TUN1 Mainstay Tunneler  
 Other Accessories  
The Lead is designed to be placed using a commercially available 7 Fr Introducer Kit  (not 
included with ReActiv8)  and the Mainstay Model TUN1 Tunneler (included with ReActiv8) or 
commercially available equivalent . 
The ReActiv8 delivers stimulation via electrodes placed adjacent to the medial branch of the 
dorsal ramus nerve  at the preferred location  as it crosses the L3 transverse process. The 
electrodes are located at the distal end of a Stimulation Lead that is connected to an 
implantable pulse generator (IPG) placed i n a surgical pocket typically above the buttocks (in a 
place similar to that used in Spinal Cord Stimulation implants). Two leads are placed (one each 
left and right side) and connected to the IPG. The IPG is externally programmable with a 
Programmer. Stimulation is manually initiated by an external device (Activator) and can be 
stopped with the Activator or Magnet.  
The leads incorporate a fixation mechanism that consists of two sets of 3 point tines –  one 
facing forward and one facing backwards. The tines are positioned to lie on either side of the 
intertransversarii lateralis, thus reducing the risk of lead dislodgement by either advancement or 
retraction. The lead body is a polyurethane tube containing spiral wound multi -filar wires  and 
incorporates a lum en to allow passage of a stylet.   
3.2. Surgical Implantation and Device Activation  
Surgical implantation is adapted from familiar techniques used for medial branch rhizotomy and 
spinal cord stimulation. Details of the recommended surgical procedure, device prog ramming 
and use by the Subject  are to be found in the Implant and Programming Manual and the User 
Manual.  
In normal use, f ollowing implantation and a suitable recovery period, the IPG is programmed to 
deliver stimulation that elicits smooth contraction of the lumbar multifidus. Typical parameters 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 23 of 84 Document Number 950057, Rev. E 25-MAR -2017 
are 0.5 mA, 200 μs, 20  Hz, with 10 seconds of stimulation followed by  20 seconds of no 
stimulation , delivered for a Session of 30 minutes. Refer to the Implant and Programming 
Manual for device programming.  
To star t a Session, the Subject  is posi tioned comfortably prone or lying on the side.  The Subject  
initiates delivery of electrical stimulation with the Activator, which can also be used to stop 
stimulation (e.g.: in case of interruption). Two sessions of stimulat ion, each of 30 minutes, are 
delivered each day (e.g. morning and evening).  
3.3. Physician  Training  
All physicians who will implant any portion of the ReActiv8 in the clinical Trial will participate in 
product training as outlined in the Training Strategy . A “C ertificate of Completion” will be issued 
to each implanting physician who completes the training to the satisfaction of the trainer.  
All physicians and other health care personnel who will interact with the programmer (e.g.: non-
implanting physicians) will  receive training from the Sponsor, which includes lectures and use of 
a programmer with a simulator (e.g.: a ReActiv8 IPG connected to a dummy load). This training 
will also include interaction with the external components handled by the Subject, including the 
Activator and Magnet.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 24 of 84 Document Number 950057, Rev. E 25-MAR -2017 
4. Study Design  
International, multi -center, prospective, randomized, sham controlled, blinded Trial with an 
adaptive statistical design.  
4.1. Hypothesis  
In Subjects with chronic low back pain and no prior surgery and with unsatisfactory pain relief 
despite medical management (including at least physical therapy and medications), episodic 
electrical stimulation of the medial branch of the dorsal ramus nerves to cause contraction of the 
lumbar multifidus muscles can lead to relief of  low back pain  and the disabling effects of back 
pain.  
4.2. Proposed Indications for Use  for ReActiv8  
ReActiv8 is an adjunct to medical management in adults with Chronic Low Back Pain for 
relief of  pain in subjects who have failed at least medical management and physical 
therapy.  
4.3. Study Population 
Subjects with chronic low back pain that impacts their daily living, who satisfy the following 
general criteria:  
1 Chronic low back pain and di sability despite medical management, including at least 
one attempt of physical therapy treatment for low back pain (which may optionally be 
accomplished over multiple episodes or flare -ups of low back pain) , and may be 
using prescribed pain relieving drugs (including muscle relaxants) which have been 
at a stable appropriate dose for a minimum of 30 days . 
2 No contraindications for enrollment . 
Detailed Inclusion and Exclusion criteria are listed in Section 5. 
4.4. Study Size and Duration  
A minimum of 116 evaluable S ubjects is required to sufficiently power the primary endpoint. To 
allow for attrition, 1 28 Subjects will be randomized as part of the Intent to Treat Cohort.  Up to 80 
additional Subjects will be randomized as part of the Surgical Roll In phase as described below  
(assuming one implanting surgeon per site) . Therefore,  the total number of implanted and 
randomized Subjects will be up to 2 08. In order  to account for screen failures prior to implant  up 
to 800 Subjects will be enrolled.  An adaptive statistical design using a single  interim look will be 
used for sample size re -estimation.  
4.4.1.  Investigati onal Sites  
Investigators may include a number of different specialties including Physical Medicine and 
Rehabilitation (PM&R) , Interventional Pain, Neurosurgery, Neurology and Spine Surgeons. The 
key investigational activities include Subject  recruitment, device implant, and Subject  follow up 
(including device management and T rial data collection). Some investigators will perform  all of 
these activities , and some may not . For example, some PM&R physicians  will not perform 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 25 of 84 Document Number 950057, Rev. E 25-MAR -2017 
surgery, and the surgery will be performed by a Sub -investigator (e.g.: a neurosurgeon) who 
may be at a different site. The T rial design accommodates this situation.  
There will be up to 40 investigational  sites with a Principal Investigator who may or may not be 
the implanting physician. One or more Sub -investigators per site (or affiliated site if the affiliated 
site has a different Ethics Committee or IRB) may be used for example for device implantation 
and Subject  recruitment.  
4.4.2.  Surgical Roll In Phase 
Following training, up to the first two Subjects implanted by the same implanting physician may 
be prospectively included in a Surgical Roll I n group and not included in the Intention To Treat 
Cohort.  The Surgical Roll In phase for each implanting physician will be deemed complete upon 
consultation with the implanting physician and the Sponsor . In some cases,  there will be no 
Surgical Roll In phase, for example if the implanting physician participated in the ReActiv8- A 
Trial. Note that Subjects incl uded in the Surgical Roll In Phase who are not successfully 
implanted are not included in the Surgical Roll In group.  
All Subjects implanted  in the Surgical Roll In group will be randomized to either T reatment or 
Control, and follow the identical visit schedule as Subject s included after the Surgical Roll In 
phase.  With approximately 4 0 implanting physicians and up to 2 S ubjects in the Surgical Roll In 
phase per implanting physician, up to 80 Subjects may be included in the Surgical Roll In group.  
4.4.3.  Study Duration  
Total study duration is anticipated to be ≤ 60 months from first Subject  Baseline Visit through 
PMA submission . 
Informed consent for all Subjects will allow for continuing data collection for a total period of 7 
years from Baseline Visit. 
4.5. Assessment of Lumbar Multifidus Dysfunction  
The Prone Instability Test (PIT) has been utilized in variety of studies55 and is used in this T rial 
to identify S ubject s likely to have multifidus dysfunction. The PIT was designed to identify 
Subjects who would likely respond to a lumbar stabilization exercis e program, and in many of 
these Subjects spine instability is thought to be due to LM  dysfunction consequent to 
compromised neural drive to the LM . It has established reliability (K = 0.87).56 It was one of 4 
variables shown to be predictive of success with a stabilization exercise program for S ubjects 
with low back pain that included exercises designed to reactivate the LM.57 Additionally, the 
same study demonstrated that those Subjects who had a positive PIT also had reduced LM 
thickness change when compared to Subjects who had a negative PIT. The PIT may be the 
only predictive test that has demonstrated reasonable inter -tester reliability.58 
The PIT will be performed by appropriately qualified individuals (e.g.: physical therapist, 
Physical Medicine and Rehabilitation Physician, Or thopedic Surgeon).  Each person performing 
the PIT shall undergo training as follows:  
• The training materials  shall be standardized across sites.  
• The person conducting the training shall be a reputable and appropriately qualified 
individual  with experience in training on the PIT (e.g.: a physical therapist or physical 
medicine physician who regularly conducts training of other specialists) . 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 26 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• A formal training plan shall be developed in conjunction with the trainer(s) , including 
“hands on” conduct of the PIT.  
• Each trainee will be assessed by the trainer, including a “hands -on” demonstration of 
competence in performing the PIT to validate the training.  
• Upon successful completion of the training and assessment , the trainer shall sign  a 
“Certificate of  Training” for the trainee to document that the trainee is qualified to conduct 
the PIT for this T rial. 
In summary, t o conduct the PIT, the S ubject is positioned prone on an examination table. The 
test is conducted in two stages:  
Stage 1:  Tester performs Posterior -Anterior (P -A) glides over each lumbar segment for pain 
provocation and identifies the painful segments.  
Stage 2:  Repeat P -A with hips extended (Feet just off of the floor) as shown in Figure 1. 
A Positive Test is when any previously painful segments become pain- free. The level of  
instability will be documented.  
 
Figure 1: Conducting the Prone Instability Test  
4.6. Outcome Measures  
Several outcome measures are used t o assess  the primary and secondary endpoints of the 
Trial. 
4.6.1.  Low Back Pain Visual Analog Scale (VAS)  
The primary outcome measure is pain, a Patient Reported Outcome (PRO). The instrument 
used for evaluating pain is the  continuous  Visual Analog Scale comprised of a horizontal line 
10cm  in length, anchored by 2 verbal descriptors, one for each symptom extreme for Low Back 
Pain, as recommended by IMMPACT.44  

 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 27 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Subjects will be advised to place a line on the VAS that represents their average low back pain 
for the last 7 days. The scale is anchored with “no pain”  on the left side of the scale to “worst  
imaginable pain”  on the right side of the scale .  
Note:  This is a study on low back pain. Thus the Subject will be presented a VAS  that is 
specific to the low back pain that led to being enrolled in this study. This allows 
separation of the low back pain symptoms from other pain causing events (e.g.: 
toothache) which could confuse interpretation of the results. People with low back pain 
often also report leg pain, which should be distinguished from the low back pain that led 
to enrollment in the T rial. 
The VAS for low back pain is  recorded by the Subject  at each of the visits and is used for the 
primary outcome.   
A daily Journal will also be collected for 7 days  prior to each visit through the 120 day follow -up, 
completed preferably at the same time of day ( e.g.: between 5PM and 8PM).  
4.6.2.  ODI 
Oswestry Disability Index (ODI) is a disease specific assessment of the disabling effects of back 
pain.48 The ODI covers 1 item on pain and 9 items on activities of daily living (personal care, 
lifting, walking, sitting, standing, sl eeping, sex life, social life, and traveling). ODI is reported as a 
score from 0 to 100%.  
The relevance of changes in ODI has been explored by many authors, and discussions abound 
on Minimal Clinical Important Difference (MCID), Minimally Important Chang e (MIC) and the 
like. It is important to distinguish between significance of change scores for studies on acute  low 
back pain where the natural history of improvement would suggest reversion to the mean, and 
studies on chronic low back pain where the likelihood of improvement is low. Hägg et al59 
suggested that an absolute change of 10 (in the 100 point ODI scale) is the MCID and Ostelo60 
concurs that a Minimally Important Change is 10.   
4.6.3.  EQ-5D 
EQ-5D is the acronym for the European Quality of Life Score on Five Dimensions.  There are 
many instruments used for assessment of Quality of Life,61 and EQ -5D appears to be the most 
commonly used in studies of therapies for back pain, and is often used for cost utility 
assessment.62 The EQ -5D descriptive system comprises the following 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. The original EQ -5D used a 3 
level reporting system (no problems, some problems, extreme problems), and more recently a 
five level reporting system has been developed and validated (no problems, slight problems, 
moderate problems, severe problems , and extreme problems), referred to as the EQ -5D-5L, 
which has been tested and validated.63,64 This Clinical Investigation uses the EQ -5D-5L, referred 
to in its short form as EQ -5D. 
The EQ -5D is designed for use primarily as a sel f-reported measure (i.e.: the questionnaire is 
completed by the Subject  alone), and therefore lends itself to clinical trials in which the outcome 
assessment is to be blinded. Population norms for EQ -5D for various populations have been 
reported, and categorized by age, gender and social class.  EQ-5D is reported as an index up to 
1.00 (note: EQ -5D index scores of <0 are possible in some circumstances).  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 28 of 84 Document Number 950057, Rev. E 25-MAR -2017 
4.6.4.  Percent Pain Relief (PPR)  
Percent Pain Relief (PPR) is a  question asked to the Subject by the Investigator or Coordinator  
in which the Subject  is asked to report the percent pain relief at the time of the current visit  
compared to the pain at baseline.  
4.6.5.  SGIC  
Subject Global Impression of Change ( SGIC) is based on the “Patient Global Impression of 
Change” as described by Farrar.65 The Subject  is presented with a questionnaire with 7 choices , 
as shown in Figure 2. 
Since I enrolled in the study, my overall status is  
1. □ Very much improved  
2. □ Much improved  
3. □ Minimally improved  
4. □ No change  
5. □ Minimally worse  
6. □ Much worse  
7. □ Very much worse  
Figure 2: Subject Global Impression of Change (SGIC) Questionnaire  
4.6.6.  Clinical Global Impression 
Clinical Global Impression –  Global Improvement consists of the questions that are to be 
completed by the Investigator as shown in Figure 3. 
In your opinion as a clinician, compared to the S ubject’s 
situation at baseline, would you say the S ubject is:  
□ Much better  
□ Slightly better  
□ About the same  
□ Slightly worse  
□ Much Worse  
Figure 3: Clinical Global Impression Ques tionnaire 
4.6.7.  Resolution of Back Pain  
Resolution of back pain (cure) is defined as a  Subject  with 7 day average low back pain VAS  
≤2.5cm on the 10cm  VAS.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 29 of 84 Document Number 950057, Rev. E 25-MAR -2017 
4.7. Clinical Trial Endpoints  
A single primary endpoint will be analyz ed. Multiple secondary endpoint s and exploratory 
endpoints will be analyzed.  
4.7.1.  Primary Endpoint – Low Back Pain VAS 
The Primary Efficacy Endpoint is a comparison of responder rates between Treatment and 
Control groups, where a “responder” is a Subject with ≥ 30% reduction from baseline in average 
low back pain VAS without any  increase  from baseline in pain medication and/or muscle 
relaxants prescribed and taken in the two weeks prior to the Primary Endpoint A ssessment  Visit. 
Note:  The primary outcome measure is intended to assess the efficacy of 120 days of 
stimulation. Thus the visit for assessment of the primary outcome  must occur no sooner 
than 120 days post randomization.  
Records of pain medications will be collected along with all other medications used for treatment 
of low back pain, which are also being collected for analysis of secondary and cost -
effectiveness endpoints. The Subject  will re port medications taken at each scheduled follow -up 
visit. Rescue medications taken on an exceptional basis for acute pain conditions other than 
back pain will also be documented and their possible effect examined as part of sensitivity 
analyses.  
After the Primary End point Assessment Visit , Subjects will be permit ted to adjust their drug use 
as appropriate, based on consultation with their physicians, and data on drugs prescribed and 
taken will continue to be collected.  
4.7.1.1.  Hypotheses  
The primary efficacy objective will be assessed by the following hypotheses:  
H0: Π VAS T = ΠVAS C 
HA: Π VAS T ≠ ΠVAS C, 
where Π VAS T is the proportion of S ubjects meeting primary success criteria in the Treatment 
group and Π VAS C is the proportion of subjects meeting success criteria in the Control group. 
The hypotheses will be tested using a two- sided binomial test for a difference in proportions. 
The objective will be met if a statistically significant difference favoring the Treatment group is 
found.  
The study will be considered a success if the primary efficacy objective is met.  
4.7.1.2.  Sample Size Ra tionale  
The sample size for the study is determined under the following assumptions for the primary 
efficacy endpoint:  
• Minimum power of 80%  
• Type I error of 5%  
• Assumed primary efficacy success in Treatment  group: 50%  
• Assumed primary efficacy success in Cont rol group: 25%  
Under the above assumptions, a minimum of 116 evaluable S ubjects is required in order to 
demonstrate superiority of the ReActiv8 treatment. The total sample size is increased by 10% to 
128 to allow for attrition.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 30 of 84 Document Number 950057, Rev. E 25-MAR -2017 
An adaptive statistical design using a single interim look will be used for sample size re-
estimation  when at least 50% of the implanted S ubjects have completed the P rimary Endpoint 
Assessment Visit. Details of the interim analysis are provided in the Statistical Analysis Plan.  
4.7.2.  Secondary Efficacy Endpoints  
All tests of significance will be tested utilizing an overall Type I error of 5% . The overall Type I 
error will be maintained by utilizing Hochber g’s method to test the collection of the first five 
secondary objectives. These will be tested only if the primary efficacy endpoint is met.  
1. Comparison of change from baseline in Oswestry Disability Index (ODI) between Treatment 
and Control groups at  the Primary End point Assessment Visit . 
2. Comparison of change from baseline in EQ -5D between Treatment  and Control  groups at 
the Primary Endp oint Assessment Visit  
3. Comparison of Percent Pain Relief between Treatment  and Control  groups reported by the 
Subject  at the Primary Endp oint Assessment Visit  
4. Comparison of Subject Global Impression of Change at the Primary Endp oint Assessment 
Visit 
5. Comparison of number of S ubjects with Resolution of Low Back Pain (remitters or cure, 
defined as a VAS score ≤ 2.5cm ) at the Pri mary End point Assessment Visit  
6. Evaluation of changes in primary and secondary efficacy metrics in the Crossover Group (as 
defined in Section 4.10 ) following the Outcome Post Crossover V isit. 
4.7.2.1.  Hypotheses  
ODI 
The ODI efficacy  objective will be tested under the following hypotheses:  
H0: µODI T = µODI C 
HA: µODI T ≠ µODI C 
Where µODI T is the me an change in ODI in the Treatment  group and µODI C is the mean change 
in ODI in the Control group at the Primary Endp oint Assessment Visit. The hypotheses will be 
tested using a two -sided two- sample t -test for a difference in mean change s. 
In addition, a cumulative proportion of responder analysis of ODI will be performed.51 
EQ-5D 
The EQ -5D efficacy  objective will be tested under the following hypotheses:  
H0: µEQ5D T = µEQ5D C 
HA: µEQ5D T ≠ µEQ5D C 
Where µEQ5D T is the mean change in EQ -5D (index score) in the Treatment group and 
µEQ5D C is the mean change in EQ -5D in the Control group from baseline to the Primary 
Endpoint Assessment Visit. The hypotheses will be tested using a two- sided two -sample t -test 
for a di fference in mean changes.  
Percent Pain Relief  
The secondary Percent Pain Relief efficacy  objective will be tested under the following 
hypotheses  
H0: µPPR T = µPPR C 
HA: µPPR T ≠ µPPR C 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 31 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Where µPPR T is the mean percent pain relief in the Treatment  group and µPPR C is the mean 
percent pain relief in the Control  group at the Primary Endp oint Assessment Visit . The 
hypotheses will be tested using a two- sided two -sample t -test for a difference in mean change s. 
Subject Global Impression of Change  
The secondary Subject Global Impression of Change efficacy  objective will be tested under the 
following hypotheses  
H0: DISTRIBUTION SGIC T = DISTRIBUTION SGIC C 
HA: DISTRIBUTION SGIC T ≠ DISTRIBUTION SGIC C 
Where DISTRIBUTION SGIC T is the distribution of the  Global Impression of Change in the Treatment  
group and DISTRIBUTION SGIC C is the distribution of  Global Impression of Change in the Control  
group at the Primary End point Assessment Visit . The hypotheses will be t ested using a two-
sided Mann -Whitney test.  
Resolution of Low Back Pain  
The secondary Resolution efficacy  objective will be tested under the following hypotheses:  
H0: ΠRLBP T = ΠRLBP C 
HA: ΠRLBP T ≠ ΠRLBP C 
Where ΠRLBP T is the proportion of S ubjects with a VAS back pain assessment for the previous  
7 day of  VAS ≤2.5cm  (on a 10cm scale) in the Treatment group and ΠRLBP C is the proportion 
of Subjects with a VAS back pain assessment for the previous  7 day average VAS ≤2.5cm  in 
the Control  group at the Primary Endp oint Assessment Visit. The hypotheses will be tested 
using a two -sided binomial test for a difference in proportions . 
4.7.3.  Primary Safety Assessment  
The primary safety assessment is of serious device and/or procedure related adverse events in 
all Subjects in the Intent to Treat Cohort at the P rimary Endpoint Assessment V isit. All reported 
adverse events will be documented and reported with summary statistics presented for 
observed rates. There are no formal, statistical hy potheses being tested in the safety 
assessment.  
4.7.4.  Supporting Safety Analysis  
The PMA Submission will include 12 month safety data on all Subjects implanted with ReActiv8 
including all S ubjects implanted in the ReActiv8 -B Trial  for whom 12 month safety data are 
available, and other persons implanted with ReActiv8 in other clinical trials (including the 
ReActiv8 -A PMCF Study ) and all post -marketing registries that are registered on 
www.clinicaltrials.gov . This data will be provided as a separate analysis of the safety on all 
implanted persons as  an appendix to the ReActiv8- B Trial results.  
A separate safety assessment will be performed on the Surgical Roll In Cohort , including a 
poolabi lity analysis.  
4.7.5.  Supporting Analyses  
The supporting efficacy analyses will include:  
• Once data are complete, all primary and secondary outcome measures will be assessed at 
12 months and compared to baseline within the Treatment group. The analysis will also 
explore correlation of outcomes to amount of stimulation delivered.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 32 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Note:  For all supporting analyses, amount of stimulation delivered will be defined as the 
number of minutes stimulation was delivered divided by the number of minutes that 
stimulation could have been delivered.  
• In the Crossover Group, outcome measures will be assessed at the Outcome Post 
Crossover Visit for all S ubjects who met the inclusion criteria for low back pain at the 
Primary Endpoint Assessment Visit (i.e.: prior to Crossover) ( Prior  week average Low Back 
Pain, VAS of ≥6 .0 cm and ≤9 .0 cm on a 10  cm VAS scale) and inclusion criterion for ODI 
(Oswestry Disability Index score ≥2 1% and ≤60% ). The analysis will also explore correlation 
of outcomes to a mount of stimulation delivered . 
• Comparison of daily average VAS averaged over the prior 7 days of Journal entry with the 
single point VAS of recollection of prior 7 days of average pain.  
• Comparison of EQ -5D VAS between Treatment and Control groups at each visit at which 
EQ-5D is recorded through 12 months.  
• For both the Treatment  and Control  groups , a cumulative proportion of responder analysis, 
so that the entire distribution of treatment response is depicted in a graph of the proportion 
of responders for all percentages of low back pain VAS reduction from 0% to 100%. In this 
manner, the number of S ubjects with ≥50% low back pain VAS improvement  can be 
deter mined, for example.   
• Subject Global Impression of Change at 12 months. The analysis will also explore 
correlation of outcom es to amount of stimulation delivered.  
• Treatment Satisfaction Questionnaire at 12 months. The analysis will also explore 
correlation of outcomes to amount of stimulation delivered.  
• Clinical Global Impression –  Global Improvement (clinician assessment) at 12 months. The 
analysis will also explore correlation of outcomes to amount of stimulation delivered.  
• Change in opioids used for treatment of low back pain from baseline to 12 months . The 
analysis will also explore correlation of outcomes to a mount of stimulation delivered.  
Additional, ad hoc exploratory analyses may also be conducted.  
Note  that t he supporting analyses may be incomplete at the time of PMA submission since not 
all Subjects may have reached 12 months post -randomization.  
4.7.6.  Health Economics  
Cost-effectiveness of ReActiv8 therapy, extrapolated to the lifetime of the device, will be 
measured. Key economic outcome measures to be recorded will be:  
• Change in work status at all visits.  
• Change in consumption of medications taken for low back pain at  all visits compared to 
Baseline. Note that an analysis may be performed of different categories of medications 
including for example opioids, muscle relaxants and anti -depressants.  
• Assessment of health care utilization (office visits, hospital visits, eme rgency room visits, 
and other  therapies such as physical therapy) at all visits  past the endpoint visit . 
Note that both the Treatment  and Control  group Subjects are required to keep medications 
constant from randomization until the Primary End point Assessment Visit , and other health care 
utilization will be as per the protocol (e.g.: no additional therapies, see Section 5.3 ). Experience 
in the ReActiv8- A Clinical Trial has shown that some subjects who experience relief from low 
back pain may reduce their pain medications (despite instructions to keep medications 
constant), and some subjects may increase medications (thereby classifying them as non -
responders). All changes in medications will be recorded.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 33 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Following the Primary End point Assessment Visit , all S ubjects will be permitted to adjust 
medicati ons and to use other health care resources. For the Crossover G roup, this may yield 
some information on how S ubjects will adjust medications during the treatment phase.  
Note that completion of the Health Economics assessments is likely to be incomplete at the time 
of PMA submission for ReActiv8, since not all S ubjects will have reached the 12 month point at 
that time.  
4.8. Control Arm  
The intent of eliciting multifidus contraction is to retrain the motor control system  and reactivate 
the multifidus for improved spine stability . Based on data from the Feasibility Study and the data 
available to date in the ReActiv8- A Trial, t here is no straightforward dose response (i.e.: there is 
a spectrum of responses to the same dose) , and the time to measurable response is different 
between Subjects . Furthermore, there is no known “sub -threshold” stimulation which is 
indistinguishable to the S ubject from “therapeutic stimulation”, and therefore a perfect sham is 
not possible.   
The Control Arm for this Trial is Subjects implanted with ReActiv8, and the output programmed 
to deliver a minimum level of electrical stimulation.  This is a sham in the sense that all S ubjects 
receive some level of electrical stimulation, and S ubjects in the Control Arm may experience 
sensations as a result of the stimulation.  
In particular, C ontrol Arm Subjects will be subject to the following stimulation:  
• Three stimulation pulses  of 0.1mA and 31µ s duration delivered between the IPG can 
(-ve) and the most proxi mal electrode ( +ve) on the lead ipsilateral to the location of the 
IPG delivered every two minutes during a stimulation session.  
• Electrical pulses (4 pulses of 31µs, 0.4mA) to assess electrode impedance of the 
programmed electrode a t the start of every sti mulation session.  
The risk of bias is addressed by the following:  
• All randomized S ubjects will have implant surgery. Thus any possible placebo effect due 
to surgical intervention will be the same in both arms.  
• All Subjects with have the same follow up schedule until the endpoint assessment. Thus 
any response due to the Hawthorne effect66 will be the same in both arms.  
• All Subjects will be instructed to have the same device interactions (lie down, press 
“start” and get up after 4 0 minutes –  30 minutes s timulation and ten minutes’  rest). Thus 
any placebo response due to the device interacti ons or simply lying down and relaxing 
for 80 minutes  per day will be the same in both arms.  
• All Subjects will experience interactions with the programmer at the follow up visits. In 
particular, all S ubjects will have battery state, lead impedance and compl iance data read 
out from the IPG.  
• Subjects in both arms may or may not experience sensations associated with the 
stimulation. It is likely that S ubjects in the Treatment group will perceive muscle 
contraction. It is possible that S ubjects in the Control group will experience a brief 
muscle twitch every two minutes , and possibly one or more muscle twitches at the start 
of each session in response to the electrical impedance testing pulses.  
• The proposed primary endpoint is binary (e.g., success or failure), and thus the S ubject 
needs to reach a substantial level of pain reduction in order to be counted as a success. 
This makes it less likely that a placebo effect will bias the study results . 
 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 34 of 84 Document Number 950057, Rev. E 25-MAR -2017 
 
4.9. Blinding and Blinding Assessment  
The following persons will be blinded to S ubject allocation to T reatment or Control Arm: 
1. Subjects  
2. Investigators  (but may become unblinded as a result of managing any AEs)  
3. Other healthcare providers (e.g.: primary care physicians)  
4. Members of the Adjudication Committees  
Subjects will not be informed of allocation to T reatment or C ontrol at any time  prior to the 
Primary Endpoint Assessment Visit. Subjects in the Crossover Group will feel LM  contractions 
with stimulation, and are likely become unblinded following  crossover . There will not be a 
Blinding Assessment at any time after the Primary Endpoint Assessment Visit.  
Measures taken to improve the likelihood of maintaining blinding of Subjects include:  
• Careful wording in the Informed Consent –  e.g.: “you may or may not feel  a sensation  during 
participation in this Trial. The effect of the treatment may not be achieved until sometime  
after initiation of treatment as every person reacts differently to treatment. Nevertheless, the 
treatment may be providing an effect, and therefore it is important that you continue to follow 
instructions at every daily treatment session.”  
• Subjects will be advised to not tell anyone of the sensations they experience,b or the 
treatment they received, including other Subjects, Investigators, outcom e assessors, and 
Sponsor  personnel.  
• Subjects will be advised in the informed consent that the output parameters of the ReActiv8 
IPG may be adjusted up or down at any time in a follow up visit. 
• Use of carefully scripted Subject  interaction with I nvestigator s, coordinators and Sponsor  
personnel at each follow up visit.  
• Investigators will be blinded as to randomization assignment  of Subjects at all times until 
primary endpoint data are available (unless managing an AE requires unblinding of the 
Subject’s randomization assignment ). 
• Persons performing interview based S ubject assessments will be blinded as to S ubject 
allocation.  
• All me mbers of the adjudication committee will be blinded as to S ubject allocation.  
• Subjects will be instructed to not compare notes with other S ubjects in the Trial, and in 
particular to not use the internet to share experiences with other S ubjects, as doing so a 
seriously prejudice the results of the Trial. 
• During the clinical T rial prior to  the primary outcome assessment, public information 
available from the Sponsor (e.g.: the web site) will be carefully worded with regard to 
sensations perceived with stimulation from the ReActiv8.  
The primary outcome measure is average low back pain VAS completed  alone by the Subject at 
the visits  without assistance. Thus the endpoint assessment is inherently blinded since no 
assessor is involved.  
After endpoint data collection at the Primary Endpoint Assessment Visit , all Subjects will 
complete a questionnaire to assess blinding. It is anticipated that the Treatment group will be 
 
b  Subjects will be advised that if they experience pain, discomfort, or any untow ard effect, then they should contact the site 
research coordinator  and not discuss with anyone else.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 35 of 84 Document Number 950057, Rev. E 25-MAR -2017 
found to be predominantly unblinded becaus e they will have felt muscle contraction and it is 
expected that those Subjects whose back pain has impro ved will assume they are in the 
Treatment group. It is anticipated that the Control group will be approximately 50% unblinded.  
The blinding assessment questionnaire for Subjects is shown in Figure 4, and based on the 
methods suggested by Bang.67 
Do you thi nk you were in the Treatment or Control group?  
 □ Treatment  □ Control  □ No idea 
How certain are you of your answer?  
 □ Strongly believe  □ Somewhat believe  □ No idea 
Figure 4: Blinding Assessment Questionnaire  
The Subject  may experience an adverse event that requires the Investigator to be made aware 
of the Subject ’s randomization assignment. Unblinding should only occur in circumstances 
where there is a risk to Subject  health or safety and every attempt should be made to contact 
the Sponsor  before unblinding the Subject ’s randomization assignment . In addition, every 
attempt should be made to keep the Subject  blinded to the randomization assignment, unless 
the Investigator believes that the Subject  should be made aware in order to manage the 
adverse event.  If it is necessary to unblind the Subject ’s randomization assignment , 
documentation of this will be provided through a study deviation case report form.  
4.10.  Crossover  
The clinical effect is not reversible since removal of stimulation from a Subject  who already has 
restored motor control is unlikely to result in return of the back pain or disability . Thus neither a 
double crossover nor a randomized withdrawal is  possible. However, a single crossover is 
possible.  
After collection of all endpoint data at the Primary Endpoint Assessment Visit, all Subjects in the 
Control  group wil l have the ReActiv8 IPG programmed to deliver S ubject appropriate stimulation 
to cause strong smooth contraction of the multifidus.  
4.11.  Data Collection  
To avoid introduction of bias, all S ubject reported endpoint data at S ubject contact visits will be 
collecte d before any other intervention or interview during the S ubject follow up. The data 
collection session shall not be attended by people not necessary for the data collection (e.g.: 
Investigator , the Subject ’s relatives or friends, or Sponsor personnel).  
Programming the ReActiv8 and data collection via the Physician Programmer will be performed 
by the Investigator or delegate, with the assistance (if requested) of personnel from the Sponsor 
or CRO under Investigator direction and guidance.  
4.12.  Stimulation Complia nce 
Subjects will be required to deliver stimulation for 60 minutes per day up to the Primary 
Endpoint Assessment V isit, typically in two Sessions of 30 minutes each. The IPG contains data 
logging of the times for start and stop of each stimulation S ession, and the data will be collected 
and recorded at each follow up visit.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parties without prior consent 
from Mainstay Medical and are not to be used in any unauthorized way.  
Page 36 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Note:  ReActiv8 does not allow stimulation greater than the maximum programmed number of 
minutes in any day (midnight to midnight), which is set at 60 by default.  
Note :  A Session can be prematurely stopped with the M agnet or the A ctivator, and stimulation 
can be restarted to complete the Session later in the day.  
Following the Primary Endpoint Assessment Visit,  Subjects in the T reatment group will be 
advised to continue to  deliver stimulation for 60 minutes per day (in two 30 minute S essions), 
but will be permitted to reduce the amount of stimulation as desired . 
Subjects in the Crossover Group will be advised to continue to deliver stimulation for 60 minutes 
per day up to t he Outcome Post Crossover Visit. Thereafter, S ubjects will be advised to 
continue to deliver stimulation in two 30 minute sessions  per day  but will be permitted to reduce 
the amount of stimulation as desired.  
Subjects should be encouraged to contact site personnel if they find that they are unable to 
complete a Session for any reason.  
For the purposes of analyses, “stimulation compliance”  will be defined as the amount of time 
spent delivering stimulation compared to the amount of time that stimulation coul d have been 
delivered in any period, expressed as a percentage. For the purposes of this analysis, “session 
compliance” will be defined as the number of Sessions during which 100% of the stimulation 
that could have been delivered actually was, during any period.  
4.13.  Statistical Plan  
The Statistical Analysis Plan is a separate document which should be read in conjunction with 
this document.  
Post-hoc analyses may be conducted but will not form part of the PMA submission.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent from Mainstay Medical  and are not to be used in 
any unauthoriz ed way.  
Page 37 of 84 Document Number 950057, Rev. E 25-MAR -2017 
4.14.  Trial Schema  
The Trial Schema is shown in outline in Figure 5. The summary data collection schedule is shown in Table 2. 
 
Figure 5: Trial Schema  
 
Informed Consent , 
Baseline data 
collection, 
inclusion decision 
ReActiv8 
Implant  
Randomization & 
Activation  
Time from Randomization  
 12 Months  
1 
1 
 2 
 4 
5 
 7 
 8 
 9 
 11 
Visit Number  
Post Surg. 
Follow Up  
8 
Endpoint 
Assessment  
10 
10 
 7 
 5 
Treatment Arm  
Control  Arm 
3 
0 
14 days  
 75 Days  
120 Days  
 180 Days  
 240 Days  
9 
A 
Annual  
Crossover  
Group  
8a 
6 
6 
45 Days  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent from Mainstay Medical  and are not to be used in 
any unauthoriz ed way.  
Page 38 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Table 2: Summary Data Collection Schedule  
All Subjects  
 
T = Treatment Group Only  
 1 Informed Consent, Baseline 
Data, Inclusion decision 2 ReActiv8 Implant Procedure 
(1-45 days post inclusion)  3 Post-Implant Follow Up 
(7 -0/+10 days  4 Randomization and 
Activation (14 ± 3 days)  5 14±7 Days Post 
Randomization  6 45±7 Days Post 
Randomization  7 75±10 Days Post 
Randomization  8 Endp oint: 120 - 0/+20 Days 
Post Randomization  8a Cross over and Activation  
(Crossover Group only)  9 180 ±30 Days Post 
Randomization  10  240± 30 Days Post 
Randomization  11 12 Months - 30/+60 Days 
Post Randomization   Annual Follow Up 360 ±60 
Days Post Randomization  Unscheduled Visit  
Screening data  (including PIT) and MRI review                
Psychological Assessment                
ODI               
Back Pain VAS (Journal)                
Back Pain VAS (Single Point)                
Medications Questionnaire                
EQ-5D               
DASS 21               
Low Back Pain Descriptive Characteristics                
Work Status Evaluation                
Percent Pain Relief                
Subject Global Impression of Change (SGIC)                
Treatment Satisfaction Questionnaire (TSQ)                
Clinical Global Impression (CGI)                
Health Care Utilization                
Blinding Assessment Questionnaire                
X-Ray (AP and Lateral)               ? 
Device Measurements & Stimulation thresholds     T T T T T       
Interrogate IPG for lead impedance & compliance                
Physical Exam & Surgical Site Exam                
Adverse Events                
Pregnancy Test                
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 39 of 84 Document Number 950057, Rev. E 25-MAR -2017 
5. Subject Selection and Withdrawal  
5.1. Inclusion Criteria 
1. Age ≥22c years , ≤75 years  
2. 7 day  recall of A verage Low Back Pain VAS of ≥6.0cm and ≤9.0cm at baseline (on a 10cm 
scale)   
3. Oswestry Disability Index score ≥2 1% and ≤60% at the Baseline Visit.  
4. Chronic Low Back Pain defined as pain and discomfort localized below the costal margin 
and above the inferior gluteal fold (with or without referred leg pain) that has persisted >90 
days prior to the Baseline  Visit, which has resulted in pain in at least half of the days in the 
12 months prior to the Baseline Visit, as reported by the Subject . 
5. Evidence of lumbar multifidus muscle dysfunction by the Prone Instability Test (PIT).  
6. Continuing low back pain despite >90 days  of medical  management including:  
a. At least one attempt of phy sical therapy treatment for low back pain , which may 
optionally be accomplished over multiple episodes or flare -ups of l ow back pain. 
NOTE 1: Subjects who start a physical therapy program but are unable to complete it are 
still eligible with regards to thi s inclusion criterion.  
NOTE 2: Subjects who participated in a physical therapy program in the past since the 
onset of low back pain but are unwilling or unable to participate in a new physical 
therapy program are still eligible with regards to this inclusi on criterion;  
b. For Subjects with m edications prescribed and used for chronic low back pain, usage 
shall be at a stable dose in the 30 days prior to the Baseline Visit as reported by the 
Subject . 
NOTE 3: A stable dose means the S ubject reports no significant change in regular use of 
medications, which may include PRN use,  in the 30 days  prior to the Baseline Visit. 
7. Be willing and capable of giving Informed Consent  
8. Ability to comply with the instructions for use and to operate ReAc tiv8, and to comply with 
this Clinical Investigation Plan.  
9. Suitable for ReActiv8 surgery as determined by the implanting physician prior to inclusion.  
5.2. Exclusion Criteria 
1. BMI > 35  
2. Back Pain characteristics:  
a. Any surgical correction procedure for scoliosis at  any time, or a current clinical 
diagnosis of moderate to severe scoliosis (Cobb angle ≥25°) . 
b. Lumbar spine stenosis, as defined by an anterior -posterior diameter of the spinal canal 
of <10mm in Subjects with lower extremity pain.  
c. Neurological deficit possi bly associated with the back pain (e.g. foot drop).  
d. Back pain due to pelvic or visceral reasons (e.g.: endometriosis or fibroids) or infection 
(e.g.: post herpetic neuralgia).  
e. Back pain due to inflammation or damage to the spinal cord or adjacent structur es (e.g. 
arachnoiditis or syringomyelia) . 
 
C As per the FDA definition of an adult    
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 40 of 84 Document Number 950057, Rev. E 25-MAR -2017 
f. Pathology  seen  on MRI that is clearly identified and is  likely the cause of the CLBP  that 
is amenable to surgery . 
g. Back pain due to vascular causes such as aortic aneurysm and dissection.  
3. An independent assessment of any current indication for back surgery according to 
appropriate  guidelines, or has indications for back surgery but cannot undergo surgery for 
other reasons.  
4. Leg pain described as being worse than back pain, or radiculopathy (neuropathic pain) 
below the knee.  
5. Source of pain is the sacroiliac joint as determined by the Investigator.  
6. Drug use per Subject report as follows:d 
a. Current baseline use of >120mg oral morphine equivalent per day of opioids.  
b. Current use of breakthrough dose of >60mg oral morphine equivalent per day  
c. Current requirement of  opioids for treatment of a condition other than low back pain.  
d. History of any substance abuse at any time in the five years  prior to the Baseline  Visit. 
e. Current ly taking >15mg Diazepam per day or equivalent . (See Table 3)  
7. Surgical or other procedures exclusions:  
a. Any previous rhizotomy or rhizolysis procedure, including cryoablation, RF ablation or 
pulsed RF on the dorsal root ganglion (DRG) or the medial branch of the dorsal ra mus 
nerve that crosses or lies below the T8 vertebra, within one year prior to the Baseline 
Visit. 
b. Anesthetic block of the DRG or medial branch of the dorsal ramus nerve that crosses 
or lies below the T8 vertebra or injection of epidural steroids for back pain in the 30 
days prior to the Baseline  Visit. 
c. Any previous back surgery including laminectomy or discectomy at or below segmental 
level T8, or spinal fusion at any level . 
d. Any previous thoracic or lumbar sympathectomy.  
8. Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, pars 
defect,  or lumbar annular tear with disc protrusion that is amenable to surgery . 
9. Planned surgery:  
a. Any major surgery (including elective surgery) planned in the twelve months following 
the Baseline Visit (does not include minor surgeries not expected to impact the lumbar 
spine (e.g. colonoscopy) ). 
b. Any elective surgery of any kind (including, for example, tooth extraction, gynecological 
surgery,  or cosmetic surgery) in th e time between the Baseline Visit and the Primary 
Endpoint Assessment Visit . 
10. Any co-morbid chronic pain conditions . 
11. Other clinical conditions:  
a. Pregnant or planning to be pregnant in the next 12 months, at the time of inclusion.e  
b. Pregnancy at any time in the 6 months, or lactating in the 3 months, prior to the 
Baseline Visit.  
 
d  The reason for exclusion of Subjects on high doses of narcotics or anti -depressants is that these doses may have altered 
the CNS to the extent that the therapy may not work, there is a possibility of addiction that may not resolve even after back  
pain symptoms are reduced or eliminated, and there is a possibility that a significant portion of the Subject’s back pain 
symptoms are secondary to opioid induced hyperalgesia  
e  Subjects will be advised that if they  become pregnant or plan to become pregnant after the Primary Endp oint Asses sment 
Visit, the Activator will be withdrawn and the IPG programmed to OFF to preve nt any stimulation delivery during pregnancy . 
The IPG may be reprogrammed and the Activator returned if the Subject requests following completion or termination of the 
pregnancy.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 41 of 84 Document Number 950057, Rev. E 25-MAR -2017 
c. Any condition unrelated to the CLBP such as muscle wasting, muscle atrophy, other 
disability (e.g.: paraplegic, amputee , cerebral palsy ) or muscular or skele tal disease 
(e.g.: arthritis in trunk or limbs, multiple sclerosis , rheumatoid arthritis ) which, in the 
opinion of the Investigator, could limit physical movement or compliance with the 
protocol, or interfere with the assessment of efficacy of the investigational procedure.  
d. Poorly controlled diabetes (Type I or Type II) determined by HbA1c >8.  
e. Past or current neurological disorders (e.g.: known multiple sclerosis, motor neuron 
disease, Guillain- Barré syndrome, Parkinson’s, Huntington’s Disease, Alzheimer’s , 
epilepsy, stroke, brain cancer, traumatic brain injury).  
f. Cancer requiring treatment during the study.  
g. Any drugs (e.g.: immunosuppressive drugs) or co -morbidity that might inhibit wound 
healing or electrode scarring, or drugs associated with reduced effec tiveness of 
neuromodulation for other applications.  
h. Any medical condition requiring anticoagulation (other than aspirin) that, in the opinion 
of the physician prescribing the anticoagulant, cannot be safely suspended for 5 days 
prior to device implantation surgery and an appropriate period after implantation 
surgery.  
i. Any active infection in the vicinity of the implant site or any systemic infection.  
12. Psycho -social exclusions  
a. Be involved in an injury claim under current litigation.  
b. Have a pending or approved financial compensation claim (e.g.: worker’s 
compensation claim, long term disability claim)  or any financial compensation (including 
social welfare payments) related to the Subject’s CLBP . 
c. Current incarceration (prison or jail)  
d. Have an assessment  of current active depression significant enough (DASS 
depression score >9) to impact perception of pain, compliance with intervention and/or 
ability to evaluate treatment outcome.  
e. Have evidence of an active disruptive psychological or psychiatric disorder  or other 
known condition significant enough to impact perception of pain, compliance with 
intervention and/or ability  to evaluate treatment outcome  (e.g.: active depression, 
bipolar disease, Alzheimer’s disease)  as determined by a psychologist or psychiat rist. 
13. Protocol Compliance Exclusions  
a. Inability or unwillingness to comply with all protocol requirements.  
b. Inability to maintain the prone or side lying position in a relaxed manner for the duration 
of each  stimulation session.  
c. Inability to operate the Acti vator, such as arthritis that limits arm or shoulder movement, 
or inability to learn how to operate.  
d. Inability to assess changes in pain intensity or perform wound care.  
e. Inability or unwillingness to complete the Journal.  
14. General exclusions  
a. Any other active implantable device including an implantable device for back pain (such 
as an implantable drug pump or Spinal Cord Stimulator), pacemaker, implantable 
defibrillator, cochlear implant, deep brain stimulator, implantable drug pump, or other 
implanted neurostimulation device.  
b. Prior exposure to an implantable neurostimulator for treatment of pain, including spinal 
cord stimulation  (including trial implant of SCS leads) , occipital nerve stimulation or 
peripheral nerve stimulation.  
c. A condition currently req uiring or likely to require use of MRI or diathermy while 
implanted with the ReActiv8 .  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 42 of 84 Document Number 950057, Rev. E 25-MAR -2017 
d. Therapy with any other investigational intervention (drugs, devices, or procedures) for 
the treatment of back pain at the time of the Baseline Visit, or at any time in the past if 
the past investigational intervention did not subsequently gain regulatory approval.  
e. Current or planned participation in any other clinical trial during participation in this 
Trial.  
f. Life expectancy <1 year  
Table 3: Benzodiazepine Equivalents  
Drug  Dose Equivalent to 15mg Diazepam (mg)  
Alprazolam  1.5 
Alprazolam extended release  1.5 
Chlordiazepoxide  30 
Clonazepam  0.75 
Clorazepate  22.5 
Estazolam  0.9 
Flurazepam  15 
Lorazepam  3 
Oxazepam  45 
Prazepam  45 
Quazepam  15 
Temazepam  15 
Triazolam  0.3 
5.3. Other Therapy During the Trial  
5.3.1.  Medication 
Subjects shall be advised to not make any change to medications for treatment of low back pain 
at the time of the Subject ’s inclusion in the T rial until the Primary Endpoint Assessment Visit . 
This includes medications for pain and muscle relaxants. Subjects will be informed that they 
may reduce, increase or discontinue medications for low back pain following the Primary 
Endpoint A ssessment Visit .  
Subjects will be informed tha t if they believe they need any change in prescription medications 
for treatment of low back pain during the T rial, then they should contact the Investigator  who will 
arrange for modification of type or dose of pain medications, as clinically necessary, and the 
data will be recorded. Subjects will be told that they should not request modification to 
prescribed drugs for their low back pain from any non- study physician during the period from 
baseline until the Primary End point A ssessment Visit . Any change in medications for other 
conditions (e.g.: hypertension) are allowed if prescribed by the Subject’s regular treating 
physician.  
All Subjects shall continue on any and all prescribed medication deemed medically necessary 
and not prescribed for t he indication of CLBP (e.g.: antihypertensive medicines, statins, thyroid 
medications, diabetes medication, and low -dose aspirin).  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 43 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Any change in pain medication prescribed and taken over the 14  days prior to the 120 day visit 
shall be reported by the Subject  at the visit. If the prescribed dose is PRN, the S ubject shall 
report  the use of the drug over the prior two week s if it changed from that taken at baseline.  
5.3.2.  Physiotherapy & Exercise  
Subjects will be instructed to go about their daily lives as best  as possible, and encouraged to 
be active.  
If the S ubject has previously participated in an exercise program or other physical activity (e.g.: 
aerobic exercises, weight training, home exercise machine, team or solo sports) then that 
exercise may continue o r resume at the discretion of the Investigator , following the 
Randomization Visit. Such exercise s hould not be performed between I mplant and the 
Randomization Visit to allow time for healing of the surgical scar.  
Any additional exercise is to be allowed at  the discretion of the Investigator , subject to the 
Subject’s ability to perform exercise. To avoid bias, no specific physiotherapy or other exercises 
to treat CLBP are allowed between the Baseline and Primary Outcome Assessment Visit .  
Strenuous activity that could exacerbate the underlying condition of low back pain shall be 
forbidden until after the Primary End point Assessment Visit (e.g.: chopping wood, rowing, heavy 
weight lifting, and wrestling).  
5.3.3.  Other Devices or Therapy  
Use of othe r devices or therapy is likely to confound the results of the Trial. Therefore,  with the 
exception of medication, all therapies targeted at the low back pain will be prohibited during the 
Trial. Subjects should be instructed to not use any other devices such as braces, belts, TENs 
devices, acupuncture, chiropractic manipulation, massage or anything else which is not 
specifically required by this protocol.  
It is especially important that the following procedures not  be performed during the T rial 
because they  will directly affect the device itself and/or its ability to interact appropriately with 
the body , or may affect endpoint assessment : 
• Epidural injections  
• Nerve ablations of any kind for low back pain  
• Any other interventional pain procedures for low back pain (e.g.: nerve blocks)  
• Any physical procedure (e.g.: back or gluteal massage or chiropractic adjustment) that 
carries a risk of dislodging leads  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 44 of 84 Document Number 950057, Rev. E 25-MAR -2017 
6. Subject Contact and Data Collection Schedule  
Subject contact will be according to the following schedule. Any  unscheduled visits will be 
recorded.  
Note : All data collection shall be done as the first thing in the follow up visit, prior to any other 
procedures.  
Note : Adverse event data will be collected at each visit after the Baseline Visit. 
6.1. Visit 1: Informed Consent , Baseline Data , Inclusion 
Decision  
The process for obtaining informed consent shall be in compliance with FDA regulations 
(21CFR  50) and ISO 14155.  
Subjects will be provided with the Subject Information and Informed Consent Form which 
advises that dat a will be collected for evaluation of eligibility for inclusion in the Trial. Subjects 
are told that if the criteria are met and the Subject  consents, then the ReActiv8 will be 
implanted.  
If the Subject  agrees to inclusion for data collection, the Subject Informed Consent will be 
signed and recorded in the Subject ’s records at Visit 1.  
The Subject  will be assigned a unique study identifier.  
Data to be collected during the visit:  
• Screening data as required by the inclusion/exclusion criteria documented in Subject  study 
records  
• Medical History  (including Physical Exam)  
• Low Back pain descriptive characteristics  
• 7 day recall of Average Low Back Pain VAS  as reported by the S ubject  
• Work  status evaluation  
• Medications (all medications including indication)  
• ODI 
• EQ-5D 
• DASS 21 
• Healthcare Utilization 
Activities to be performed:  
• Journal:  
o Instruct the Subject in the use of the Journal and provide the Journal.  
• Prone Instability Test  to assess lumb ar multifidus dysfunction.  
• Answer any questions the Subject may have, and confirm willingness to proceed if the 
baseline criteria are verified.  
• Verify that the inclusion/exclusion criteria are satisfied.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 45 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• An MRI of the lumbar region of the low back will be performed or ordered if there are no MRI 
images from more recently than 180 days prior to Visit 1. MRI images will be reviewedf to 
assess conditions that may be a possible cause of low back pain and to rule out possible 
surgical candidates by institutional guidelines.  
• Pregnancy test in women of child bearing potential.  
• Assessment by the Investigator of the Subject’s suitability for ReActiv8 implant which 
includes review of the psychological  asses sment  (e.g. mental fitness).  
NOTE: The surgical assessment and other required assessments may be performed at any 
time prior to Visit 2, and still be included in the Visit 1 data collected. If the implanting 
physician determines that the Subject is not a suitable candidate for the procedure, 
then the S ubject shall not be scheduled for implant , will be withdrawn from the T rial, 
and will not be included in the analysis.  
• If the S ubject meets the inclusion criteria, s chedule the surgery for the ReActiv8 implant  and 
discuss with the Subject . Ensure that all hardware necessary for the procedure is available, 
and schedule support staff.  
6.2. Visit 2 : Implant Procedure  
The implant procedure should take place as soon as possible following the verification of 
baseline criteria, at a minimum of 1 day and maximum of 45 days following Visit 1. The duration 
of the implant procedure visit depends on local institutional practices and Subject  condition post -
implant , and may be as short as a few hours (e.g.: for an outpatient procedure), or as long as 
several days.  
Data to be collected prior to implant :  
• Medications  
Data to be collected during or post implant : 
• Surgical notes  
• Adverse Events (including Adverse Events prior to the Implant Procedure, and any adverse 
events associated with the Implant Procedure).  
• Measurement and recording of electrode impedance and stimulation thresholds as defined 
in the Implant and Programming Manual  
NOTE: The Subject  should preferably be unconscious (i.e.: general anesthesia) during 
assessment of electrode impedance and stimulation thresholds. If local anesthesia is 
used, then appropriate medication should be administered to minimize the chance 
that the  Subject  will remember the procedure.  
Activities to be performed after implant procedure:  
• Make a (de -identified) digital record of fluoroscopic images taken during the implant 
procedureg including at least bi -plane (AP and lateral) radiographic images of electrode 
positi on that shows the entire implanted system from the distal tip of the electrodes to the 
whole IPG . 
 
f  All Images to be de- identified and included in the data record for the Subject  in an electronic format to allow analysis at a 
later date.  A core lab may be used for evaluation of MRI images as part of the supplementary data analysis.  
g  It is a requirement for a site to participate in the trial that digital recording of fluoroscopic images should be available  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 46 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• Inspect  the surgical s ite prior to hospital discharge 
• Program IPG to OFF (i.e.: default state is no electrical output from the IPG).  
NOTE: Regular post -surgic al follow up per institutional guidelines in the first 7 days post -
implant  are included in the Implant Procedure Visit.  
6.3. Visit 3 : Post- Implant  7 -0+10 Days  
A Post -Surgical Follow  Up visit should be performed between 7 and 17 days  post-implant . 
Data to be collected  
• Adverse Events  
Activities to be performed:  
• Examination of the surgical wounds  (Physical Exam and Surgical Site  Exam ) 
• General post -surgical clinical care  
• Removal of sutures (Note: it is recommended that sutures be removed no sooner than 11 
days post -implant  to reduce the risk of infection)  
6.4. Visit 4 : Randomization & Activation Visit 14 ± 3 days 
Post Implant  
Randomization shall be 14 ± 3 days from the date of implant  (to allow for scheduling). Visit 3  
and Visit 4 may be combined.  
If the Subject  is unable to use the device for any reason (e.g.: injury, infection, other new clinical 
condition) at the time of the R andomization  Visit, then the Randomization Visit may be 
postponed up to 30 days to allow the issue to resolve without incurring a protocol devi ation.  
Note:  A decision to delay randomization must be done before the Subject  is randomized.  
Data to be collected:  
• Adverse events  
Activities to be performed:  
• Inspect surgical wound to verify healing, and remove sutures  (if not previously removed) . 
Address any clinical issues associated with the surgical procedure (Physical Exam and 
Surgical Site  Exam ) 
• Confirm  Subject allocation to Treatment or Control g roup has been completed.  
For Subjects in the Treatment Group Only:  
• Perform electrode impedance and threshold measurements and record results  
• Program IPG  to Subject  appropriate levels  
For Subjects in the Control Group Only:  
• Program IPG to Control  
For all S ubjects:  
• Train in use of the Activat or and document assessment of Subject’s ability to sel f-administer 
therapy twice a day starting the next day . 
• Train in the procedure to deliver stimulat ion, including time of day and S ubject positioning.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 47 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• Provide encouragement to contact site personnel if any  difficulty is encountered delivering 
stimulation or completing a Session.  
6.5. Visit 5 : 14±7 Days Post Randomization  
Data to be collected:  
• Single point average low back pain VAS over previous week as reported by the S ubject  
• Adverse events  
• AP and lateral X -Rays that clearly shows the entire implanted system from the distal tip of 
the electrodes to the whole IP G. 
Activities to be performed:  
• Inspection of surgical site (Physical Exam and Surgical Site Exam)  
• Provide the pain Journal and instruct the Subject i n the use of the Journal  for 7 days prior to 
the next scheduled visit . 
• Remind Subject to continue to lie down and activate therapy twice daily.  
• Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored i mpedance measurements  
Note:  Provide encouragement to all Subjects to continue to apply therapy using the Activator 
twice a day. If compliance assessment shows <90% compliance, additional counseling 
may be provided.  
For Subjects in the Treatment Group Only:  
• Device activities:  
o Electrode impedance and threshold measurements, and data collection 
o Adjustment of stimulation configuration and amplitude as appropriate  
6.6. Visit 6 : 45±7 Days Post Randomization  
Data to be collected:  
• Pain Journal:  
o VAS for daily average low back pain  
• 7 day recall of Average Low Back Pain VAS as reported by the S ubject  
• Pain m edications  prescribed and taken  
• Low Back Pain descriptive characteristics  
• Work  status evaluation  
• Adverse events  
Activities to be performed:  
• Inspection of surgi cal site (Physical Exam and Surgical Site Exam ) 
• Collect Journal, and p rovide new Journal and instruct the S ubject to continue to complete 
Journal assessments  7 days prior to the next scheduled visit . 
• Remind Subject  to continue to lie down and activate therapy twice daily.  
• Readout from IPG of stimulation delivery times and duration (compliance assessment) , 
battery state, and stored impedance measurements  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 48 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Note:  Provide encouragement to all Subject s to continue to appl y therapy using the Activator 
twice a day. If compliance assessment shows <90% compliance, additional counseling 
may be provided.  
For Subjects in the Treatment Group Only:  
• Device activities:  
o Electrode impedance and threshold measurements, and data collection  
o Adjustment of stimulation configuration and amplitude as appropriate  
6.7. Visit 7 : 75±10 Days Post Randomization  
Data to be collected:  
• Pain Journal:  
o VAS for daily average low back pain  
• 7 day rec all of Average Low Back Pain VAS as reported by the S ubject 
• Low Back Pain descriptive characteristics  
• Work status evaluation  
• Oswestry Disability Index  
• EQ-5D 
• Pain m edications  prescribed and taken  
• Percent  Pain Relief  
• Adverse events  
• Subject Global Impression of Change (SGIC)  
• Treatment Satisfaction Questionnaire (TSQ)  
• Clinical Global Impression –  Global Improvement (CGI -I) 
Activities to be performed:  
• Inspection of surgical site (Physical Exam and Surgical Site)  
• Collect Journal, and p rovide new Journal and instruct the S ubject to continue to complete 
Journal assessments  7 days prior to the next scheduled visit . 
• Remind Subject  to continue to lie down and activate therapy twice daily.  
• Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored impedance measurements  
Note:  Provide encouragement to all Subject s to continue to apply therapy using the Activator 
twice a day. If compliance assessment shows <90% compliance, additional counseling 
may be warranted.  
For Subjects in the Treatment Group Only:  
• Device activities:  
o Electrode impedance and threshold measurements, and data collection 
o Adjustment of stimulation configuration and amplitude as appropriate  
 
 
 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 49 of 84 Document Number 950057, Rev. E 25-MAR -2017 
6.8. Visit 8 : 120 -0/+20 Days Post Randomization  
This Primary End point Assessment Visit must be performed no sooner than 120 days post 
randomization to ensure all S ubjects have at least 120 days of treatment or control.  At this visit 
Subjects in the Control group may now be programmed to appropriate stimulation levels and will 
be considered part of the Crossover group.  
Data to be collected:  
• Pain Journal  
o VAS for daily average low back pain  
• 7 day recall of Average Low Back Pain VAS  as reported by the S ubject  
• Low Back Pain descriptive characteristics  
• Work status evaluation  
• Oswestry Disability In dex 
• EQ-5D 
• Pain m edications  prescribed and taken  
• Percent  Pain Relief  
• Subject Global Impression of Change (SGIC)  
• Treatment Satisfaction Questionnaire (TSQ)  
• Clinical Global Impression –  Global Improvement (CGI -I) 
• Adverse events  
• Blinding  Assessment  
Activities to be performed after endpoint data collection:  
• Collect Subject’s Journal  
• Inspection of surgical site (Physical Exam and Surgical Site Exam ) 
• Device activities:  
o Electrode impedance and threshold measurements  
o Readout from IPG of stimulation deliv ery times and duration (compliance assessment), 
battery state, and stored impedance measurements  
o Adjustment of stimulation configuration and amplitude as appropriate  
• For Subjects in the Control group,  assessment of thresholds and programming of the 
ReActiv 8 IPG to a Subject  appropriate level that result  in strong smooth contractions of the 
multifidus . These Subjects now form the Crossover Group.  
Note:  At the Primary End point Assessment Visit , all Subjects are advised that they can vary 
their medications for  back pain as needed or desired.  
6.9. Visit 8a: Crossover and Activation  
Subjects in the Crossover Group  require additional  activities and data collection, which may be 
done as part of V isit 8 or can be scheduled as an additional visit . 
Data to be collected:  
• Adverse events (after threshold assessment and IPG programming)  
Activities to be performed:  
• Device activities (if not already done):  
o Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored impedance measurements  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 50 of 84 Document Number 950057, Rev. E 25-MAR -2017 
o Electrode impedance and threshold measurements, and data collection 
Adjustment of stimulation configuration and amplitude as appropriate  
6.10.  Visit 9 : 180 ± 30 Days Post Randomization   
Data to be collected:  
• 7 day rec all of Average Low Back Pain VAS as reported by the S ubject  
• Low Back Pain descriptive characteristics  
• Work status evaluation  
• Oswestry Disability Index  
• EQ-5D 
• Pain m edications  prescribed and taken  
• Percent  Pain Relief  
• Adverse event  
• Device measurements and stimulation thresholds  
• Subject Global Impression of Change (SGIC)  
• Treatment Satisfaction Questionnaire (TSQ)  
• Clinical Global Impression –  Global Improvement (CGI -I) 
• Health care Utilization  
Activities to be performed:  
• Inspection of surgical site (Physical Exam and Surgical Site Exam ) 
• Device activities:  
o Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored impedance measurements  
o Electrode impedance and threshold measurements, and data collect ion 
o Adjustment of stimulation configuration and amplitude as appropriate  
6.11.  Visit s 10: 240 ± 30 Days Post Randomization  
Data to be collected:  
• 7 day rec all of Average Low Back Pain VAS over previous week as reported by the Subject  
• Low Back Pain descriptive characteristics 
• Work status evaluation  
• Oswestry Disability Index  
• EQ-5D 
• Pain m edications  prescribed and taken  
• Percent  Pain Relief  
• Adverse event  
• Device measurements and stimulation thresholds  
• Subject Global Impression of Change (SGIC)  
• Treatment Satisfaction Questionnaire (TSQ)  
• Clinical Global Impression –  Global Improvement (CGI -I) 
• Health care Utilization  
Activities to be performed:  
• Inspection of surgical site (Physical Exam and Surgical Site)  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 51 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• Device activities:  
o Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored impedance measurements  
o Electrode impedance and threshold measurements, and data collection 
o Adjustment of stimulation configuration and amplitude as appropriate  
6.12.  Visit s 11: 12 Mont hs 0-30/+60 Days Post Randomization  
Data to be collected:  
• 7 day recall of  Average Low Back Pain VAS as reported by the S ubject  
• Low Back Pain descriptive characteristics  
• Work status evaluation  
• Oswestry Disability Index  
• EQ-5D 
• Pain m edications  prescribed and taken  
• Percent  Pain Relief  
• Adverse events  
• Device measurements and stimulation thresholds  
• Subject Global Impression of Change (SGIC)  
• Treatment Satisfaction Questionnaire (TSQ)  
• Clinical Global Impression –  Global Improvement (CGI -I) 
• Health car e Utilization  
Activities to be performed:  
• Inspection of surgical site (Physical Exam and Surgical Site Exam ) 
• Device activities:  
o Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored impedance measur ements  
o Electrode impedance and threshold measurements, and data collection 
o Adjustment of stimulation configuration and amplitude as appropriate  
6.13.  Annual Follow Up  
All Subjects will be scheduled for an Annual Follow Up following Visit 11 until such time as 
ReActiv8 obtains  US regulatory approval  or the Trial is abandoned. Following US regulatory 
approval, all S ubjects who continue with ReActiv8 implanted will have continuing A nnual Follow 
Up for 7 years from the date of randomization.  
Data to be collected:  
• 7 day recall of Average Low Back Pain VAS  as reported by the S ubject  
• Low Back Pain descriptive characteristics  
• Work Status Evaluation 
• Oswestry Disability Index  
• EQ-5D 
• Pain m edications  prescribed and taken  
• Percent  Pain Relief  
• Adverse events  
• Subject Global Impression of Change (SGIC)  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 52 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• Treatment Satisfaction Questionnaire (TSQ)  
• Clinical Global Impression –  Global Improvement (CGI -I) 
• Health care Utilization Inspection of surgical site (Physical Exam and Surgical Site)  
• Device measurements and stim ulation thresholds  
• Device activities:  
o Readout from IPG of stimulation delivery times and duration (compliance assessment), 
battery state, and stored impedance measurements  
o Electrode impedance and threshold measurements, and data collection 
o Adjustment of stimulation configuration and amplitude as appropriate  
6.14.  Unscheduled Visits  
If an unscheduled visit occurs for any reason, the following data will be collected prior to any 
other activities.  
• 7 day recall of Average Low Back Pain VAS  as reported by the Subject  
• Adverse events  
Activities to be performed:  
• Inspection of surgical site (Physical Exam and Surgical Site Exam ) 
If an unscheduled visit occurs because of a suspected Adverse Device Effect (ADE) related to 
stimulation, then device testing shall be performed to investigate a suspected device failure.  
Other activities to investigate the suspected ADE (e.g.: X -Ray imaging) may be performed at the 
discretion of the physician.  
If an unscheduled visit occurs to perform a device explant for any reason (e.g.: infection 
necessitating device removal, elective removal at the request of the Subject ), then additional 
data including surgical notes may be collected. Furthermore, any explanted devices or 
components shall be returned to the Sponsor following appropriate decontamination 
procedures.  
Note:  If an unscheduled visit occurs prior to the Endp oint Data Assessment Visit for a Subject  
in the Control group, then all efforts shall be made to avoid potential unblinding of the 
Subject , particularly as a result of IPG testing which may inadvertently result in delivery 
of stimulation leading to Subject -perceived muscle contraction.  
6.15.  Telephone Calls  or Electr onic contact  
The study coordinator will contact S ubjects by telephone (or electronically) prior to each study 
visit starting with the 75 day  visit through the 12 month  visit. This contact  will be to check on the 
well-being of the S ubject, remind the Subjec t of the upcoming visit, remind S ubjects to contact 
the Investigator/staff should he/she have any questions or concerns, remind Subjects to keep 
their pain medications the same as those taken at baseline, and to complete the pain J ournal 7 
days prior to th e 120 day visit. The telephone calls (or electronic contact ) should be made within 
15-25 days prior to the scheduled visit date.   
 
 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 53 of 84 Document Number 950057, Rev. E 25-MAR -2017 
6.16.  Revision/Explant Procedure  
Data to be collected prior to revision/explant :  
• Medications  
• Measurement and recording of electrode impedance as defined in the Implant and 
Programming Manual (system to be revised/explanted)  
Data to be collected during or post revision/explant procedure : 
• Surgical notes  
• Adverse Events  
• Measurement and recording of electrode impedance and stimul ation thresholds as defined 
in the Implant and Programming Manual  (newly implanted system ) 
NOTE: If the procedure occurs prior to 120 days, then t he Subject should preferably be 
unconscious (i.e.: general anesthesia) during assessment of electrode impedanc e 
and stimulation thresholds. If local anesthesia is used, then appropriate medication 
should be administered to minimize the chance that the Subject will remember the 
procedure.  
Activities to be performed after revision  procedure:  
• Make a (de -identified) digital record of fluoroscopic images taken during the implant 
procedureh including at least bi -plane (AP and lateral) radiographic images of electrode 
position that shows the entire newly  implanted system from the distal tip of the electrodes to 
the whole IPG 
• Inspect the surgical site prior to hospital discharge 
• Program IPG to OFF (i.e.: default state is no electrical output from the IPG)  
• Continue with study required visits.  
Activities to be performed after explant  procedure:  
• Explant < 120 days  post randomiz ation  
o Subject will be followed until the 120 day visit  and then exited .  
• Explant >120 days  post randomization  
o Adverse events will be collected over the last 30 days prior to exiting the study  
 
 
h  It is a requirement for a site to participate in the trial that digital recording of fluoroscopic images should be available  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 54 of 84 Document Number 950057, Rev. E 25-MAR -2017 
7. Anticipated Benefits and Risks  
7.1. Anticipated Benefits  
The purpose of electrical stimulation of the medial branch of the dorsal ramus nerve with the 
ReActiv8 is to help restore neural drive to the lumbar multifidus muscle ( LM). There are known 
clinical benefits to the restoration of neural drive to and rehabilitation of the LM  when delivered 
by guided physical therapy with image guided biofeedback including:  
• Improvements in the disabling effect of low back pain 
• Improvements in severity of low back pain  
• Reduction in recurrence of low back pain  
• Improvement in ability to handle regular daily activities, including return to work  
• Improvements in Quality of Life  
Based on the Feasibility Study performed with other devices, there are expected benefits from 
the stimulation to be delivered by the ReActiv8, including decrease in low back pain, decrease 
in disability, and improvements in quality of life.  
There may be no benefits to the Subject  as a result of participation in this Trial. 
7.2. Anticipated Risks 
All medical device treatments have the potential to cause adverse events or side effects. 
Adverse events are expected to be similar to other neurostimulation devices for treatment of 
back pain, such as spinal cord stimulators. Listed in thi s section are both known risks with spinal 
cord stimulators and peripheral nerve stimulators as well as theoretical risks for the ReActiv8.  
Additional information on  risks and anticipated adverse events is to be found in the  Implant and 
Programming Manual, which also includes warnings and precautions . 
Anticipated Adverse Events include:  
• AEs associated with the surgical procedure, including implant, revision, replacement and 
removal.  
o Acute or persistent pain including more pain than anticipated after surgery or worsened 
low back pain  
o Accidental injury to adjacent tissues, e.g. piercing structures such as muscle, blood 
vessels, nervous tissue,  or organs   
o Anxiety about surgical procedure or outcome of therapy (beyond what is reasonably 
expected)   
o Infection, including local infection of the device or surgical site, systemic infection and 
sepsis  
o Respiratory arrest, e.g. apneic spell during surgery   
o Slow, abnormal or inadequate wound healing including swelling, hematoma, seroma, or 
wound dehiscence, which may require surgical repair   
o Nerve irritation, impingement or damage, including pain, paralysis, sensory deficits or 
changes to bowel, bladder or reproductive function  
o Scarring or inflammation associated with the surgical site (beyond what is reasonably 
expected)  
o Stiffness or restriction in movement   
o Death  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 55 of 84 Document Number 950057, Rev. E 25-MAR -2017 
o Risks associated with any surgical procedure, regardless of type, including prolonged 
procedure or sequelae of anest hesia   
o Bleeding, hematoma, and bruising  
o Swelling (beyond what is reasonably expected), seroma, or cyst   
o Abandonment of implant procedure, including due to failure to achieve suitable 
stimulation thresholds in one or both leads   
o Intraoperative difficulties  implanting the device, such as inadequately seating lead into 
connector or damage to lead insulation  
o Tissue reaction to the presence of the implanted device or materials in/on the implanted 
device such as response to residual material on device or an all ergic response, e.g. 
previously unknown nickel or titanium allergy. Reaction may be local or systemic.   
• AEs associated with presence and use of the device. This includes AEs associated with 
chronic implant whether or not the device is turned on.  
o Migration of the lead, which may result in surgical revision, replacement or removal of 
device  
o Device failure including failure of the IPG, failure of the lead, or failure of any other 
implanted component which may necessitate surgical revision, replacement, or removal 
of the device or components of the device.  
o Nerve irritation, impingement or damage, incl uding that resulting from mechanical 
presence of device, exposure to electricity including electrical stimulation, or migration of 
the leads, suture sleeve or IPG. This may lead to pain, paralysis, sensory deficits or 
changes to bowel, bladder or reproduct ive function  
o Device extrusion  
o Erosion, threatened erosion or fistula formation in skin overlying device components   
o Excessive fibrotic tissue growth , including fibrotic tissue growth which may complicate 
device removal.   
o Hematoma, seroma, cyst or swelling  
o Acute or persistent pain including worsened low back pain and/or pain and discomfort 
due to presence of the device  
o Undesired sensations such as uncomfortable paresthesia, numbness, vibration, 
pressure, prickling, or uncomfortable contraction of the mul tifidus   
o Overstimulation of tissue, resulting in symptoms such as painful muscle contraction, 
paresthesia, jolts or shocks. In addition, injuries that occur as a consequence of 
stimulation, e.g. accidents that occur as a result of being startled or back injuries that 
occur due to diminished motor control   
o Infection, including local infection of the device or surgical site, systemic infection and 
sepsis  
o Death  
o Tissue reaction to the presence of the implanted device or materials in/on the implanted 
device such as response to residual material on device or an allergic response, e.g. 
previously unknown nickel or titanium allergy. Reaction may be local or systemic.   
o Skin irritation as a result of contact with the Activator  
o Tissue damage due to mechanical presenc e of device, or exposure to electricity 
including electrical stimulation  
o Contraction of muscles other than the target muscle(s)   
o Muscle fatigue, spasm or injury   
o Malfunction of other medical equipment suc h as a pacemaker due to device interactions  
o Stiffne ss, including restricted motion due to adhesions to the device  
o Psychiatric disturbance, such as anxiety or depression or complications of depression 
such as suicide  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 56 of 84 Document Number 950057, Rev. E 25-MAR -2017 
o Symptoms in unrelated systems such as nausea, insomnia, urinary retention or 
undesired weight changes, including as a sequelae of stimulation of the Subject . 
o Inability to deliver therapy, including inadequate doses of therapy. Sources include lead 
migration, device malfunction or exposure to electromagnetic fields, e.g. security 
screening devi ces  
o Electrical shock   
o Inability to stop therapy, with possible sequelae such as anxiety, restriction of 
movement, pain, muscle fatigue, postural changes, difficulty in walking, sitting or 
physical activity   
o Accidents, injuries, body movements, body positi ons or biological process which lead to 
device complications such as a fall which causes injury to the IPG, sit -ups or severe 
coughing leading to migration of the lead, or bony fracture leading to device migration or 
fracture.  
Subjects may also undergo medical/and or surgical intervention to treat the issues identified 
above.  
The ReActiv8 includes features that provide protection from EMI. Most electrical devices and 
magnets encountered in a normal day are unlikely to affect the operation of the ReActiv8.  
Sources of strong EMI can exist near high power amateur radio transmitters, near television 
towers or other equipment.  Generally, the amount of EMI present in publicly -accessible areas is 
reduced to a level that is not likely to impact the ReActi v8. Exposure to strong sources of EMI 
can result in the following effects:  
o Serious injury or death, resulting from heating of the implanted components of the 
ReActiv8 and damage to surrounding tissue.  
o Damage to the ReActiv8, resulting in a loss of or change in stimulation delivery and 
requiring surgical replacement.  
o Operational changes to the ReActiv8 IPG, causing it to turn ON or OFF (particularly if 
the IPG is enabled for magnet use) or to reset, resulting in loss of stimulation and 
requiring reprogr amming by a clinician.  
Equipment such as retail theft prevention systems and airport metal detectors may interfere with 
the ReActiv8. The S ubject should be instructed to walk directly through such systems and not 
remain near them any longer than necessary.  The presence of an implantable pulse generator 
in the body may set off security screening devices (e.g.: at airports), so it will be necessary for 
the Subject to carry a card to identify themselves to security screeners as carrying an IPG.   
Subjects with either the study device implanted or parts of the study device still implanted will 
not be able to have a magnetic resonance imaging (MRI) scan, since this test may damage the 
study device and may cause serious injury.  This risk is unchanged as long as the  system (IPG 
and leads) remains implanted.  
7.3. Risk Minimization  
Additional risks may exist. Risks can be minimized through the use of strict compliance with this 
CIP, and adherence to the guidelines for S ubject selection, site training, and close monitoring of 
the Subject ’s physiologic status at follow -up visits. In addition, the product labeling (including the 
Implant and Programming Manual and the User Manual) details warnings and precautions 
which must be followed to minimize risk to Subjects.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 57 of 84 Document Number 950057, Rev. E 25-MAR -2017 
8. Safety  
The f ollowing definitions are used:  
Adverse Event (AE):  
An adverse event is defined as any undesirable clinical occurrence that affects the 
health or safety of the Subject .  
If an adverse event leads to multiple outcomes that sequentially worsen, only the worst  adverse 
event is reported. For example, a hematoma leading to infection would be reported as a single 
AE for the  infection.  
Serious Adverse Event (SAE):  
A Serious Adverse Event is defined as an adverse event that led to death, or led to 
serious deteriorat ion in the health of the Subject , that either resulted in:  
1. a life -threatening illness or injury, or  
2. a permanent impairment of a body structure or a body function, or  
3. in-patient or prolonged hospitalization,  
4. congenital anomaly/birth defect, or  
5. medical or surgical intervention to prevent life- threatening illness or injury or 
permanent impairment to a body structure or a body function.  
Note:  Planned hospitalization for a pre -existing condition or a procedure required by 
the protocol (e.g., the index implant procedure, or device replacement due to 
normal battery depletion), without serious deterioration in health, is not 
considered a serious adverse event.  
Unanticipated Adverse Device Effect (UADE):  
An unanticipated adverse device effect means any serious adverse effect on health or 
safety or any life- threatening problem or death caused by or associated with a device, if 
that effect, problem, or death was not previously identified in nature, severity, or degree 
of incidence in the investigational plan or application, or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of S ubjects.  
For all adverse events the Investigator must determine whether the event was related to the 
device and/or procedure and document this on the eCRF. Individual events may be related to 
more than one category, e.g. an injury due to a tunneling tool may be related to Device 
Hardware and Procedure. The categories used for relatednes s are listed in Table 4.  
Table 4: Adverse Event Relatedness Categories  
Related to Device Hardware  Events reasonably anticipated to be related to the physical 
presence of the device, e.g. er osion, a device deficiency , 
loss of power.  
Related to Device Stimulation Events reasonably anticipated to be related to electrical 
stimulation, especially those that appear when the device 
is on and disappear when the device is off, e.g. undesired 
sensation experienced only when the device is turned on.  
Related to Procedure  Events reasonably anticipated to be related to procedures 
described in this protocol.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 58 of 84 Document Number 950057, Rev. E 25-MAR -2017 
All AEs will be collected from the time of informed consent through the end of t he study.  Death 
should not be recorded as a separate  adverse event, but rather as an outcome of the specific 
SAE which led to the Subject ’s death.  
Adverse Events that would be reasonably expected to be associated with a ny surgical 
procedure (e.g.: anesthes ia associated nausea, surgical site pain) will not be categorized as 
procedure or device related in the 30 days post the surgical procedure (to be adjudicated by the 
Adjudication Committee).  
The Adjudication Committee will review and adjudicate all A dverse  Events  that occur , including 
relatedness . The Committee  will also review and adjudicate all reported hospitalizations, 
regardless of whether they are classified by the Investigator as an adverse event. Safety 
Analysis will be performed on adjudicated events only.  
Notes:  
1. Any current condition that is recorded as a pre- existin g condition is not an AE, unless 
there is a worsening of that condition in terms of nature, severity, or degree of incidence.  
2. Technical observations –  an undesirable device event that does not result in a medically 
undesirable situation for the Subject  – is not an AE.  
3. Normal end of battery life of the IPG is not an AE.  
4. Suspending or stopping use of ReActiv8 due to pain relieved is not an AE.  
5. ReActiv8 removed due to pain relieved is not an AE.  
6. Planned hospitalization for a procedure required by this protocol  is not an AE . However, 
complications during the course of that planned hospitalization that prolong the  
anticipated duration of the hospitalization do constitute SAEs.  
7. Elective hospitalization for a pre -existing illness does not constitute an SAE unless the 
illness has worsened in the nature, severity or degree of the condition with respect to 
baseline.  
8. Device migration will not be collected as an AE, but rather as a device deficiency . If 
device migration results in a clinical symptom, report this as an AE in addition to the 
device deficiency report documenting device migration.  
9. Experiencing unusual sensations is a normal part of programming a neurostimulation 
device. Accordingly, symptoms felt during a programming session are not considered 
AEs unless they are caused by the final programming parameters and persist after 
completion of the programming sessi on. 
10. Lack of efficacy or diminished therapeutic response does not constitute an AE since 
failure to receive therapeutic benefit is an issue of efficacy, not safety. This includes 
symptoms that recur in the context of device deficiency leading to loss of therapy. If the 
recurring symptoms are not worse than at baseline, record the event as a device 
deficiency but not as an adverse event . 
11. Removal and/or replacement of any part of the device due to mal function would be 
considered a device related adverse event.  
8.1. Adverse Event Reporting  
The Investigator will monitor the occurrence of adverse events for each enrolled S ubject. 
Adverse events reported by the Subject  to the Investigator , confirmed by the Investigator , and 
documented in medical records must be reported on the adverse event form based on the 
requirements of the study CIP.  
All Adverse Events, all Serious Adverse Events, and all Unanticipated Adverse Device Effects 
will be reported to all Investigators and IRBs and/or Ethics Committees participating in the study  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 59 of 84 Document Number 950057, Rev. E 25-MAR -2017 
per their reporting requirements . This is done by means of an interim report or a final study 
report prepared by the Sponsor .  
8.2. Adverse Event Outcome S tatus  
Adverse Events, when reported,  are assigned a status by center s depending on the nature of 
the event or the corrective action involved. When clinically appropriate, center s should work to 
close events whose underlying clini cal condition may not be resolvable during the term of the 
investigation.  
Center s may move outcome status to “closed” or alternatively, add text to the adverse event 
description at a follow- up visit addressing that adverse event stating that the adverse event is 
ongoing but for study purposes and outcome data, the event is considered closed.  
8.3. Device Deficiencies  
A device deficiency  is an inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance. All  suspected investigational device deficiencies 
should be documented on the appropriate CRF. The Sponsor will investigate all suspected 
device deficiencies.  
Note:  a device deficiency can include a device malfunction (i.e.: failure to perform to 
specificatio ns), and may also include other deficiencies (e.g.: ambiguity of labelling).  
For the implanted components of ReActiv8, note that not all device deficiencies will lead to an 
explant. For example, loss of stimulation on one electrode may be resolved by reprogramming 
such that stimulation can be delivered on a different set of electrodes. Thus a device deficiency 
may not necessarily lead to an AE or SAE.  
If possible, a device with a suspected malfunction should be returned to Mainstay for analysis , 
including any explanted components . If it is not possible to return the device, the reason it could 
not be returned as well as its final disposition should be documented.  
Note that reporting of device deficiencies shall be separate from adverse event reporting. If 
there should be an adverse event associated with the device deficiency, then that adverse event 
should be reported on an adverse event CRF.  
8.4. Subject Deaths  
A Subject  death during the study should be reported to the Sponsor as soon as possible and, in 
any event, w ithin two working days of notification to the Investigator.  The center ’s IRB or Ethics 
Committee must be notified of any deaths in accordance with that center ’s IRB or Ethics 
Committee policies and procedures.  
Notification of death should include a detailed narrative (death letter) that provides detailed 
information describing the circumstances surrounding the death and is signed by the principal 
Investigator or authorized S ub-Investigator. The death letter should include all of the following:  
• Date and time of death  
• Place death occurred  
• Immediate cause of death 
• Whether or not the death was witnessed  
• Device status and/or activity at the time of death , if known   
• Any other circumstances surrounding the death  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 60 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• Approximate time interval from the initiating event to death (temporal course)  
• Investigator or sub- Investigator signature and date 
Any information listed above that is unavailable or unknown must be specified as such in the 
death letter.  
If the Subject  expired in the hospital, the following documentation should also be submitted:  
• A copy of the medical records for that admission (e.g., consults, test results, operative 
reports, and/or progress notes from the hospital chart)  
• Death certificate (if available)  
• Autopsy report (if applicable)  
If the Subject  expired outside of the hospital (e.g., home):  
• A copy of the most recent clinic visit (if not already submitted to the Sponsor)  
• Death certificate (if available)  
As applicable per local country regulation, the ev ent should be reported by the Investigator  to 
the appropriate regulatory bodies.  
Note that in the event of the death of a Subject  with an implanted IPG, if cremation is planned,  
then the IPG must be explanted prior to cremation. The internal battery may ex plode when 
exposed to extreme heat.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 61 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9. Data Management  
9.1. Study Assessments  
The Sponsor will be responsible for collection of the data required for this study in accordance 
with record and reporting requirements listed in FDA 21CFR812 and Part 11.  The Sponsor w ill 
use an electronic clinical database which shall have written procedures and document 
requirements.  The Sponsor or its  designated CRO (s) will verify and validate that the 
requirements for an electronic data system to receive and process data can be cons istently met.  
Security, reliability, consistency of the data will be maintained throughout the study.  Electronic 
CRF’s will be used on this study.  Only those staff at each site that are identified and designated 
by the I nvestigator and trained on eCRF data entry system will be allowed access to the eCRF 
system.  Any study assessment questionnaires that required the Subject  to complete directly, will 
be done on paper CRF’s then transferred to the eCRF system by the designated study site 
personnel.  
The electronic case report forms, and paper CRFs will reflect the contents of this study protocol.  
The CRF’s and any amendment to them will bear a version date and each page will be 
identifiable by the study, site and S ubject identification numbers.  If it is necessary to amend the 
CRF’s, the Sponsor will review the study protocol to determine whether or not an amendment to 
the protocol is necessary. Study assessments may be recorded using paper notes from which 
data are transcribed into the eCRF, may include data recorded as per institutional practice (hard 
copy or electronic), or may be recorded directly into the eCRF, as appropriate.  
9.1.1.  Medical History  
Medical history collected will include characteristics of the Subject ’s low back pain such as 
diagnosis and duration, as well as number of episodes of low back pain as well as the 
medications and procedures for treatment of low back pain that the Subject  has failed.  
The medical history will include baseline demographics as well as a small set of clinical data 
that would be collected at a typical visit to a general practitioner.  
Collection Method: Information transferred to paper CRFs or e CRF 
9.1.2.  Subject Screeni ng/Baseline  
Subject baseline and screening data collected shall include basic information (e.g., Subject  
identifier, date of enrollment , etc.) as well as a review of inclusion criteria, and a review of 
exclusion criteria.  
Additional data such as results o f a pregnancy test (if applicable) and MRI shall be recorded as 
per institutional practice and the results included in the eCRF.  
Collection Method: Information transferred to paper CRF or eCRF  if part of the site source 
documents.  
 
 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 62 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9.1.3.  Depression Anxiety Stress Scale (DASS 21) 
The DASS 21 is a paper questionnaire completed by the Subject alone and without assistance 
and results are recorded in the eCRF. Validated language specific versions are available.   
Collection method: Completed by the Subject on a paper questionnaire then transferred to the 
CRF or eCRF.  
9.1.4.  Surgical Procedure  
Surgical procedure data collected shall include relevant information during and following the 
procedure . 
Collection Method: Transferred from source documents and surgery worksheets to paper CRF 
or eCRF  
9.1.5.  Post- Operative Evaluation 
Evaluation of Subject  post-operative status will be collected at the Post -Implant  Follow -up. 
Collection Method: Transferred from source documents to paper CRF or eCRF  
9.1.6.  Physical Exam and Surgical Site Exam  (Post Implant)  
After implant, inspect the surgical site and note if healing is normal and as expected. Other 
elements of the physical exam include weight and information on any new clinical conditions not 
associated with the T rial.  
Collection Method: Tra nsferred from source documents to paper CRF or eCRF  
9.1.7.  Oswestry Disability Index  
The Oswestry Disability Index is a paper questionnaire completed by the Subject alone and 
without assistance and results are recorded in the eCRF. Validated language specific ver sions 
are available.  
Collection method: Completed by the Subject on a paper questionnaire then transferred to the 
CRF  
9.1.8.  Low Back Pain VAS 
Low back pain VAS  will be collected at each visit .  
Collection Method: Subject completes a form without assistance, and the results are transferred 
to the eCRF.  
 
 
 
 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 63 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9.1.9.  Medication 
All prescribed medications  used, regardless of indication, will be collected at the time of Subject  
Screening/ Baseline Visit. 
Medication endpoints will use the subset of this data comprised of prescribed pain medications  
and muscle relaxant  
• Primary endpoint assessment -  the metric will be based on all prescribed pain 
medications or muscle relaxants taken.  
• Secondary endpoint assessment - the metric will be limited to opioids taken for treatment 
of low back pain.  
Collection Method: Question asked by the Study Coordinator and recorded then transferred to 
the eCRF.  
9.1.10.  Treatment Satisfaction Questionnaire 
Treatment Satisfaction Questionnaire will consist of the questions shown in Figure 6. 
Are you satisfied with the outcome of your treatment?  
□ Definitely yes  □ Maybe  □ Definitely not  
Knowing what you know now, would you want this treatment again?  
□ Definitely yes  □ Maybe  □ Definitely not  
Would you recommend this treatment to another person with chronic low back pain?  
□ Definitely yes  □ Maybe  □ Definitely not  
Figure 6: Treatment Satisfaction Questionnaire  
Collection Method: Subject completes a paper form and results are transferred to paper CRF or  
into the eCRF  
9.1.11.  Subject Global Impression of Change  
Subject Global Impression of Change cons ists of the questionnaire as detailed in 4.6.5 . 
Collection method: Subject completes a paper form and results are transferred to paper CRF or 
eCRF  
9.1.12.  Clinical Global Impression – Global Improvement  
Clinical Global Impression –  Global Improvement consists of the questions that are to be 
completed by the Investigator  as shown in Figure 3 on Page 28 . 
Collection method:  Physician completes on a paper CRF which is transferred to  eCRF  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 64 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9.1.13.  EQ-5D 
The EQ -5D-5Li Quality of Life questionnaire is completed by the Subject . Validated language 
specific versions are available.  
Collection method: Subject completes a paper form and results are transferred  into the eCRF  
9.1.14.  Adverse Events  
All transient and long- term adverse events will be collected throughout the course of the study. 
Assessment will include Investigator -assessed relationship to device, relationship to procedure, 
severity  (i.e.: AE or SAE) , subsequent treatment/intervention required and resol ution status at 
each follow -up visit until the event is resolved or closed because of chronic nature of the event.  
Note that a Subject  death automatically closes any outstanding adverse events for that Subject . 
Collection Method: Paper CRF or eCRF  
9.1.15.  Device Deficiency  
Device deficiency data collection will include all device deficiencies, including suspected device 
malfunctions and deficiencies.  
Collection Method: Paper CRF or eCRF  
9.2. Management of Protocol Deviations  
An Investigator is required to conduct this s tudy in accordance with the signed Investigator's 
Agreement, this investigational plan, applicable laws and applicable national regulations, and 
any conditions of approval imposed by the reviewing IRB or Ethics Committee and regulatory 
agency ( e.g.: FDA or Competent Authority ). 
Protocol deviations are a fact of life with any clinical trial. Deviations may be anticipated (e.g.: 
known delay in a follow up visit), inadvertent (e.g.: unplanned delay or miss of a follow up visit 
due to a family emergency ), or unanticipated on an emergency basis (e.g.: trauma may require 
device removal to allow an MRI, or other contraindicated procedures).  
Except in emergency situations, protocol deviations require prior Sponsor  approval; and if the 
deviation may affect the sc ientific soundness of the plan or the rights, safety, or welfare of 
Subjects, prior IRB or Ethics Committee approval is required.  
An Investigator shall notify the Sponsor and the reviewing IRB or Ethics Committee of any 
deviation from the investigational plan to protect the life or physical well -being of a Subject  in an 
emergency. Such notice shall be given as soon as possible, but no later than five working days 
after the emergency occurred.  
All deviations from the investigational plan must be reported to  the Sponsor together with the 
reason for the deviation and possible corrective actions for the deviations. I n some 
circumstances, the center  may be required to notify the cen ter’s IRB or Ethics Committee,  and 
the Sponsor  will notify the appropriate regulatory agencies.  
 
i  See http://www.euroqol.org/   
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 65 of 84 Document Number 950057, Rev. E 25-MAR -2017 
9.3. Informed Consent  
Informed Consent is required from all S ubjects (or their legal representatives) prior to the 
Subject ’s participation in the study. The process of obtaining Informed Consent shall comply 
with the Declaration of Helsinki, FDA 21CFR  50, ISO 14155 -2011 and applicable national 
regulations (local IRB, Ethics Committee and/or Regulatory bodies , as applicable).  
The process of obtaining informed consent shall  
a) Avoid any coe rcion of or undue influence of S ubjects to participate,  
b) Not waive or appear to waive S ubject’s legal rights,  
c) Use native language that is non- technical and understandable to the S ubject or his/her 
legal representative,  
d) Provide adequate time for the S ubject to consider participation and ask questions if 
necessary,  
e) Informed consent shall always be signed and personally dated by the S ubject or legal 
representative and by the Investigator  or delegate.  
The original signed Informed Consent must be retained on file by the Investigator  and a copy 
given to the Subject (I nvestigator’s responsibility).  
9.4. Subject Classification  
All Subjects are classified as one of the following:  
 Baseline withdrawal  – refers to a Subject  who has been enrolled but then is withdrawn from 
the study before the device implant process has been initi ated. The original Informed 
Consent form for intent Subjects should be maintained in the Centre’s administrative files. 
There are no follow -up requirements for Baseline withdrawal  Subjects.  
 Attempt – refers to a Subject  who has been enrolled, and in whom a ReActiv8 implant was 
attempted (i.e.: attempt to place at least one lead) but was not completed.j All Subjects in 
whom the implant was unsuccessful will be followed for at 30 days following the implant 
attempt.  If ther e are any AEs or SAEs associated with the attempted implant, the Subject  
will be followed until resolution or closure of the AE or SAE.  
 Implant – refers to an enrolled Subject  whose implant was completed (i.e.: device remains 
implanted and the surgical wound is closed and dressed) . 
 Withdrawal  post implant  – refers to a Subject  who is determined to be inactive in the study 
due to physician discretion, Subject  choice, lost to follow -up, or Subject  death. Final status 
information will be included on all S ubjec ts as available per the Informed Consent 
document.  
9.5. Subject Data Confidentiality  
Throughout the study, confidentiality shall be maintained at all times, by all parties involved, and 
all data shall be secured against unauthorized access. Confidentiality of  each Subject  shall be 
preserved in reports and any publication of the results. Only authorized personnel and their 
designees will have access to these confidential files. Subject data may be made available to 
national and foreign regulatory agencies, heal th or other governmental authorities, under strict 
confidentiality condition. The investigational sites shall ensure that data (e.g. worksheets, 
 
j  Only one procedure for  ReActiv8 implant shoul d be attempted for each Subject, although each procedure may include 
multiple attempts to implant, e.g.: to allow for surgical challenges and need for lead repositioning.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 66 of 84 Document Number 950057, Rev. E 25-MAR -2017 
programmer printouts, medical records, digital images) forwarded to the Sponsor do not contain 
any Subject  identifying data (such as name and birth date) other than the Subject  ID. 
It is required that CRFs be entered in the electronic data entry system provided by the Sponsor. 
All CRFs require the Investigator's signature  or the Investigator’s designee.  
Source doc uments as per FDA 21CFR  812 and ISO 14155 -2011 are printed, optical or 
electronic document s including the information in original records and necessary for the 
reconstruction and evaluation of the clinical investigation. Original source data should remain at 
the investigational site . 
Any changes of the reported data should be reported to the Sponsor. When available, changes 
should be entered into the electronic discrepancy management system provided by the 
Sponsor. A participating Investigator shall provide  direct access to source data and documents 
for Trial-related monitoring, audits, IRB or Ethics Committee review, and regulatory inspection.  
All Subjects’ health information will be kept confidential in accordance with all applicable laws 
and regulations. Subjects’ health information may be used to conduct this research, as well as 
for additional purposes, such as overseeing and improving the performance of products, new 
medical research and proposals for developing new medical products or procedures, and o ther 
business purposes. Information received during the study will not be used to market to S ubjects; 
Subject  names will not be placed on any mailing lists or sold to anyone for marketing purposes.  
9.6. Record Keeping  
Investigators are required to maintain on file the accurate, complete, and current records 
relating to this investigation:  
• All correspondence with another Investigator, an IRB or Ethics Committee, Mainstay Medical, 
a monitor, or FDA or Competent Authority including required reports  
• The signed CIP  with any and all amendments  
• The approved template of the S ubject informed consent form  
• Records showing receipt, use, and disposition of all devices (including software), including:  
o Date, quantity, and serial numbers of devices received 
o Names of all persons who received, used or disposed of each device  
o Dates and serial numbers of devices returned to the Sponsor  and the reason(s) for return  
• IRB or Ethics Committee approval of the CIP and any amendments and renewals  
• Competent Authority Approval in those countries where is applicable 
• The Investigators’ agreement and the fee agreement (separate or combined)  
• The Report of Prior Investigations and/or the Investigator’s B rochure  
• The insurance certificate  
• The Implant and Programming Manual and any other documentation provided with the 
device 
• Current curriculum vitae for the principal Investigator  and all S ub-investigators  
• Monitoring letters (if applicable)  
• Interim/final reports  
• Study initiation forms  
• Study closure documents  
 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 67 of 84 Document Number 950057, Rev. E 25-MAR -2017 
In addition, to the study admi nistrative documents, S ubject records shall be appropriately filed, 
including the following:  
• Signed informed consent forms  
• Source documents used for recording data  (e.g., device characteristics at implant and follow -
up) 
• Records of any adverse event , includ ing supporting documentation 
• Records pertaining to Subject deaths during the study  
• Relevant source data  
• Any other records required by the Sponsor   
• Documents showing the dates and reasons for each deviation from the CIP  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 68 of 84 Document Number 950057, Rev. E 25-MAR -2017 
10. Study Management  
10.1.  Committees and Independent Review  
10.1.1.  Data Monitoring Committee  
A Data Monitoring Committee (DMC, or sometimes referred to as a Data and Safety Monitoring 
Board or DSMB) will be established according to ISO 14155, FDA and NIH guidelines, and will 
consist of e xperienced and knowledgeable professionals who are not I nvestigators. The DMC 
will meet periodically, or as needed, to review the results of the study and to provide safety 
oversight and professional input to make recommendations for the continuation or te rmination of 
the study based on data analysis and study related adverse events. The members of the 
committee will have access to all adverse event data and any other requested study data that 
would be necessary i n order for the group to make an assessment relative to Subject  safety.  
10.1.2.  Adjudication Committee 
As per ISO  14155 , the Sponsor is responsible for the classification of adverse events and 
ongoing safety evaluation of the clinical investigation.  
An Adjudication Committee will be established to adjudic ate reported AEs . 
The Adjudication Committee will consist of at least three independent physicians  (i.e.: not 
Investigators) , of whom two will form a quorum, and none are also members of the DMC. The 
activities will be governed by a Charter.  
10.1.3.  Independent As sessment of Surgical Candidacy  
If the site determines that the subject is not excluded based on the MRI assessment, the site will 
upload the relevant images to a Core Lab for storage and preparation for review by an 
Independent Physician Reviewer.  An appropriately trained independent physician will review the 
Subject’s MRI to assess any current indication for back surgery according to appropriate 
evidence or guidelines (e.g.: Evidence Informed Management of Chronic Low Back Pain with 
Surgery,68 the Guidelines of the American P ain Society,69 or the European Guidelines for 
Management of Chronic Non- Specific Low Back Pain2). The activities will be governed by a 
Charter.   
10.2.  Study Principal Investigator Review  
The Study Principal Investigator will review Baseline data for all subjects to confirm that they 
meet the eli gibility criteria for the trial. This review will take place prior to the study implant 
procedure (Visit 2) and will be communicated to the Site Principal Investigator  and study staff.  
The review may be performed by the Study PI or an alternate physician designated by the Study 
PI.  
10.3.  Procedures to Amend the Clinical Investigation Plan  
From time to time, an Investigator or the Sponsor may propose changes to the Clinical 
Investigation Plan. The Sponsor shall have final authority to make such changes or not.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 69 of 84 Document Number 950057, Rev. E 25-MAR -2017 
From time to time, the DMC may mandate or recommend changes to the Clinical Investigation 
Plan. From time to time, regulatory authorities may mandate or recommend changes to the 
Clinical Investigation Plan.  
All amendments to the CIP shall be agreed upon by the Sponsor  and the Investigators and be 
recorded with a justification for the amendments. In all cases of changes to the Clinical 
Investigation Plan, the local rules for approval of modifications shall be followed, including by 
way of example a submission to the IRB or Ethics Committee (either in full or to the Chairman), 
and modifications to the clinical Trial contract with the institution  if applicable.  
10.4.  Device Accountability  
Device accountability shall be in compliance with ISO 14155 and FDA regulations . 
The Sponsor will control the availability of all investigational devices (including software) by 
shipping devices only to trained representatives or study Investigators who have IRB or Ethics 
Committee , and Sponsor approval. The Sponsor shall keep records to document the physical 
location of all investigational devices from shipment of investigational devices to the 
investigation sites until return or disposal. Devices are not transferable between Invest igators 
unless prior approval is obtained from the Sponsor. Access to investigational devices shall be 
controlled and the investigational devices shall be used only in the clinical investigation and 
according to the Clinical Investigation Plan.  
The site Pr incipal Investigator or an authorized designee shall keep records documenting the 
receipt, use, return and disposal of the investigational devices, which shall include 
1. the date of receipt,  
2. identification of each investigational device (batch number/serial number or unique 
code),  
3. the expiry date, if applicable,  
4. the date or dates of use,  
5. Subject  identification,  
6. date on which the investigational device was returned/explanted from the Subject , if 
applicable, and 
7. the date of return of unused, expir ed or malfunctioning investigational devices, if 
applicable.  
An out -of-service product is defined as any implantable products (e.g. device, lead) remov ed or 
rendered inactive. Out -of-service product includes but is not limited to devices that do not 
functi on appropriately at implant and explanted product. Whenever possible, any out -of-service 
product should be returned to the Sponsor  for analysis. In the event of a Subject  death, every 
effort should also be made to return product to Mainstay Medical.  
10.5.  Labeli ng  
All investigational devices will have a clinical investigation label, which will be visible on the 
pertinent shipping cartons and storage containers. The required labels or manuals will bear the 
following information:  
• Model and serial number of the dev ice (the magnet does not have a serial number)  
• Name of the device and the address of Mainstay Medical as the manufacturer  
• Caution statement  regarding investigational device 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 70 of 84 Document Number 950057, Rev. E 25-MAR -2017 
• All relevant contraindications, hazards, adverse effects, interfering substances or 
devices, warnings and precautions  
10.6.  Data Monitoring Plan  
It is the responsibility of the Sponsor to ensure proper monitoring of the study per regulations. 
Appropriately trained Sponsor personnel or delegates appointed by the Sponsor will perform 
study moni toring at the investigation site in order to ensure that the study is conducted in 
accordance with the CIP, the signed Clinical Trial Agreement, and applicable regulatory 
requirements. The Sponsor must therefore be allowed access to the S ubjects’ clinic an d 
hospital records when so requested as per the consent form, Privacy Authorization (US only) 
and Clinical Trial Agreement. Procedures required in this CIP require source document 
verification for this study. A separate Monitoring Plan will detail levels of source verification for 
this study.  
Monitoring visits will be conducted periodically to assess study progress, the I nvestigator’s 
adherence to the CIP and regulatory compliance.  This includes but is not limited to IRB/EC 
approval and review of the study,  maintenance of records and reports, review of the consent 
process and review of source documents against Subject case report forms to ensure data 
points are correct and that adverse events are being reported. Monitors facilitate site regulatory 
and study compliance by identifying findings of non- compliance and communicating those 
findings along with recommendations for preventative/corrective actions to site personnel. 
Communication with the site personnel occurs during the visit and following the visit vi a a written 
follow- up letter. Monitors may work with study personnel to determine appropriate corrective 
action recommendations and to identify trends within the study or at a particular center.  
Frequency of monitoring visits will occur based on S ubject en rollment, timing of the study visits, 
duration of the study, study compliance, findings from previous monitoring visits and any 
suspected inconsistency in data that requires investigation. All data used for a regulatory 
submission will be monitored against  source documentation prior to the PMAA submission.  
All active sites will have a closure visit.  A closure visit is a visit that occurs after a site’s last 
required follow -up visit.  Closure visit activities may include source verification of the data and 
closure of any findings and/or study -related activities.  
Storage and accountability of investigational product used for this study will be assessed and 
monitored through out the study at each site.  
10.7.  Sponsor Responsibilities  
MML US Inc. (a subsidiary of Mainstay Medical Limited, Ireland)  (“Mainstay”) is the Sponsor of 
this study , where a Sponsor is defined as an individual or organization taking the responsibility 
and liability for the intention or implementation of a clinical investigat ion. 
It is the responsibil ity of the S ponsor to ensure proper monitoring of the study and to see that all 
clinical requirements are met. In addition, Sponsor  representatives may participate in the 
conduct of the T rial to the extent described in the followi ng section on the role of the Sponsor 
representatives. In this study Sponsor representatives are not blinded to the study results , 
particularly since Sponsor representatives may be involved in device programming. Participation 
in the study will be limited to Sponsor  personnel who are appropriately qualified and trained 
such as those personnel with an engineering, technical or nursing degree or equivalent training, 
or significant experience within the implantable device industry. All Sponsor  personnel will be 
trained on the appropriate clinical study regulations and guidelines for medical device trials.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 71 of 84 Document Number 950057, Rev. E 25-MAR -2017 
It is the responsibil ity of the S ponsor to ensure appropriate training of all individuals involved in 
the clinical T rial. This includes I nvestigators and other health c are professionals at the 
investigational sites, Sponsor  personnel, and contractors if applicable.   
10.8.  Role of the Sponsor Representatives  
Sponsor personnel can provide technical support to the Investigator  and other health care 
personnel (collectively HCP) as needed during implant, testing required by the CIP, and follow -
up visits. Support may include HCP training, addressing HCP questions, or providing 
clarifications to HCPs concerning the operation of Mainstay Medical equipment (including 
programmers and ot her support equipment) or the procedures and forms related to the CIP.  
At the request of the Investigator  and while under the Investigator ’s supervision, Sponsor  
personnel may operate equipment during implant or follow -up visits , assist with the conduct of  
testing specified in the CIP, and interact with the Subject  to accomplish requested activities. 
Typical tasks may include:  
• Interrogating the device or programming device parameters to physician requested 
settings  
• Performing lead diagnostic testing using a  programmer to obtain thresholds and 
impedance measurements  
• Clarifying device behavio r, operation or diagnostic output as requested by the 
Investigator  or other health care personnel  
• Assisting with the collection of study data from programmers and other equipment  
• Entering data on study worksheets as long as the responsible study Investigator verifies 
and signs the completed worksheet  
In addition, Sponsor  representatives or designated technical personnel can perform certain 
activities to ensure study qualit y. These activities include:  
• Observing testing or medical procedures to provide information relevant to CIP 
compliance 
• Reviewing collected data and study documentation for completeness and accuracy  
At no point  shall  personnel  from  the Sponsor  or CRO : 
• Pract ice medicine;  
• Discuss with  the Subject  the Subject ’s diagnosis  or recommend treatment;  
• Enter  data into the eCRF ; or 
• Discuss the T rial with the Subject . 
10.9.  Clinical Investigators  
This study will be conducted in accordance with FDA Regulations 21CFR  812 and ISO 14155-
2011. A detailed list of the I nvestigators’ responsibilities can be found in 21CFR  812 and ISO 
14155- 2011. The Investigator  is responsible for conducting the study in accordance with the 
investigational plan, the latest version of the Declaration of Helsinki, the signed Investigator 
Agreement and other agreements, applicable laws and regulations, and any conditions of 
approval imposed by the reviewing IRB or Ethics Committee, and FDA or Competent Authority . 
To ensure compliance with the guidelines, the Sponsor, an independent body, or a regulatory 
agency may audit the study. By agreeing to this CIP, the I nvestigators and their institutions 
accept to allow monitoring, audi ts, IRB or Ethics Committee review, and regulatory inspections 
that are related to the study. They also agree to provide authorized individuals with access to 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 72 of 84 Document Number 950057, Rev. E 25-MAR -2017 
source data and documentation as well as the right to copy records, provided such activities do 
not violate S ubject consent and Subject data confidentiality.  
The Investigator is responsible for protecting the rights, safety, and welfare of S ubjects under 
the Investigator’s care, and for the control of devices under investigation. The Investigator is 
also responsible for ensuring that informed consent is obtained in accordance with this 
investigational plan, applicable regulatory requirements, and local IRB or Ethics Committee 
requirements. The Investigator or sub -Investigator may request the presence of Sponsor  
personnel at device- related procedures.  
A list of I nvestigators and institutions participating in this study will be available upon request.  
10.10.  Investigator Selection  
In accordance with 21CFR 812 and ISO 14155 -2011 the role of the site principal Investigator  is 
to implement and manage the day -to-day conduct of the clinical investigation as well as ensure 
data integrity and the rights, safety and well -being of the S ubjects involved in the clinical 
investigation.  
If the S ponsor contracts an instituti on to conduct the clinical investigation, the institution shall 
appoint an appropriately qualified person to be Site Principal Investigator.  
The Site Principal Investigator shall:  
• Be qualified by education, training and experience to assume responsibility for the 
proper conduct of the clinical investigation; evidence of such qualifications of the 
principal Investigator  and key members of the investigation site team shall be provided 
to the Sponsor  through up- to-date CVs or other relevant documentation  
• Be ex perienced in the field of application and trained in the use of the investigational 
device under consideration 
• Disclose potential conflicts of interest, including financial, that may interfere with the 
conduct of the clinical investigation or interpretatio n of results, and  
• Be knowledgeable with the method of obtaining informed consent.  
A Site Principal Investigator and any Sub -Investigator(s) must be experienced in and 
responsible for the following:  
• Subject well -being 
• Strict adherence to the Investigational  CIP, which includes all testing requirements to 
provide for optimal safe and efficacious use of the investigational device  
• Return of explanted devices, if applicable 
• Providing the Subject  with comprehensive information about the study and documenting 
Subject  consent and data during the study  
• Addressing medical questions which might be asked, either by the Sponsor or by 
external Regulatory Agencies, during or after the study.  
• Notifying the Sponsor of any deviation from the Protocol with an explanation for the 
deviation. This notice shall be given as soon as possible, but in a timely manner after the 
deviation occurred.  
• The Investigator  will ensure that any Adverse Event is reported according to Section 8.1 . 
• Subject death during the study should be reported to the Sponsor  as outlined in Section 
8.4. 
• Submission of death letters, notes, etc. if applicable 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 73 of 84 Document Number 950057, Rev. E 25-MAR -2017 
It is acceptable for the Site P rincipal Investigator to delegate one or more of the above functions 
to an associate or sub -Invest igator. However, the Site P rincipal Investigator remains responsible 
for proper conduct of the study. The study is not transferable to other center s attended by the 
Investigator unless prior approval is obtained from the appropriate reviewing IRB or Ethics  
Committee, the Sponsor, and the appropriate regulatory authority (if applicable).  
10.11.  Publication P olicy 
A Publication Plan will be developed by the Sponsor and Investigators following approval of the 
Study, and f or the duration of the T rial, the Publication Plan shall determine what information is 
to be submitted for publication, to which journal and/or meeting, and by whom. Publications 
shall have the order of authors as determined by the Publication Plan.  
Should presentation or publication be contemplated, the Sponsor shall be provided with copies 
of any abstracts, papers or manuscripts for review and approval within a reasonable period prior 
to submittal for publication or presentation. The Sponsor shall limit its review to a determination 
of wh ether Confidential Information is disclosed and shall not attempt to censor or in any way 
interfere with the presentation or publication beyond the extent necessary to protect Confidential 
Information or to allow the Sponsor to protect its rights in patent able or copyrightable material.  
Authorship of publications shall follow  the recommendations of the International Committee of 
Medical Journal Editorsk, which may result in employees of the Sponsor being included as 
authors.  
10.12.  Payment of Subjects  
Subjects wi ll be reimbursed for reasonable transportation costs according to local institutional 
guideli nes and regulatory requirement s of up to US$550 (in local equivalent) in any calendar 
year. 
10.13.  Maintaining Compliance  
The study will be conducted according to the sti pulations of the FDA, the Declaration of Helsinki, 
ISO 14155- 2011 and all other applicable regulations  determined by country . 
10.13.1.  Study Monitoring  
Monitoring will be performed during the study to ensure that compliance with the CIP and 
applicable regulations are maintained, that data are collected in a timely, accurate and complete 
manner and that the Investigator  continues to have sufficient staff and facilities to conduct the 
study safely and effectively.  
Monitors are individuals who are designated to oversee the progress of a study. These 
individuals are appropriately trained and qualified to monitor the progres s of a study. Monitors 
will be selected and assigned by Mainstay Medical.  
 
k  http://www.icmje.org/ethical_1author.html  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 74 of 84 Document Number 950057, Rev. E 25-MAR -2017 
10.13.2.  Review of Submitted Data  
In addition to the site monitoring visits the case report forms submitted by the I nvestigators will 
be reviewed. The following activities will occur:  
• All ca se report forms will be reviewed for completeness and accuracy upon receipt or 
after entry into the electronic data capture system  
• The Investigators and/or their clinical investigation representative and/or the Mainstay 
Medical designated personnel will be contacted regarding any missing or unclear data  
10.13.3.  Securing Compliance  
In the event of repeated noncompliance, as determined by the Sponsor, a Sponsor or CRO 
representative will attempt to secure compliance by one or more actions:  
• Visiting the Investigator  
• Telephoning the Investigator  
• Corresponding with the Investigator  
If an Investigator is found to be repeatedly noncompliant with the signed agreement, the study 
CIP, applicable regulatory requirements, or any other conditions of the study, the Sponsor may, 
at its sole discretion, terminate the Investigator's participation in the study. In the event of 
termination of Investigator participation, study devices will be returned to the Sponsor unless 
this action would jeopardize the rights, safety, or welfare of the Subject . 
10.14.  Study Completion  
The Sponsor will notify each Investigator of the completion or termination of the investigation or 
of the Investigator's participation in the study. At the Sponsor’s  request, an Investigator will 
return any devices in his or her possession. The Investigato r will provide a summary to the 
Sponsor and reviewing IRB or Ethics Committee of their investigation within 3 months of study 
termination.  
The Study Completion plan which details actions and responsibilities is shown in Table 5. 
10.15.  Suspension or Premature Termination of the Trial  
The procedure to be followed as a result of suspension or premature termination of the Trial 
shall be in compliance with 21CFR  812 and ISO 14155.  
• The Sponsor may suspend or prematurely terminate either the clinical investigation in an 
individual investigation site or the entire clinical investigation for significant and documented 
reasons.  
• A principal Investigator , IRB or E thics Com mittee , or regulatory authority may suspend or 
prematurely terminate participation in a clinical investigation at the investigational sites for 
which they are responsible.  
• If suspicion of an unacceptable risk to S ubjects arises during the clinical investigation, or 
when so instructed by the IRB or ethics Committee,  or regulatory authorities, the Sponsor 
shall suspend the clinical investigation while the risk is assessed. The Sponsor shall 
terminate the clinical investigation if an unacceptable risk is confi rmed.  
• The Sponsor shall consider terminating or suspending the participation of a particular 
investigation site or Investigator  in the clinical investigation if monitoring or auditing identifies 
serious or repeated deviations on the part of an Investigator . 
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 75 of 84 Document Number 950057, Rev. E 25-MAR -2017 
If suspension or premature termination occurs, the terminating party shall justify its decision in 
writing and promptly inform the other parties with whom they are in direct communication. The 
principal Investigator  and Sponsor shall keep each other info rmed of any communication 
received from either the IRB or Ethics Committee,  or the relevant regulatory authority.  
If the Sponsor makes a decision to discontinue the study for any reason (e.g., slow enrollment , 
significant change in risk/benefit due to unanticipated adverse device effect, or other scenario), 
then the Sponsor will promptly inform all Investigators, IRBs or Ethics Committees, and relevant 
regulatory bodies along with detailed information on how enrolled S ubjects should be managed 
thereafter. A ll Subjects enrolled in the T rial will continue to be followed according to the 
investigational plan unless the Sponsor not ifies the investigational center s otherwise.  
An Investigator  may also discontinue participation in the study with suitable written notice to the 
Sponsor. Should either of these events occur, the Investigator  shall:  
• return all documents and devices to the Sponsor  
• provide a written statement as to why the premature t ermination has taken place 
• notify the IRB or Ethics Committee and the regulatory authority (if applicable)  
If suspension or premature termination occurs:  
1. the Sponsor shall remain responsible for providing resources to fulfi ll the obligations from 
the Clinical Investigation Plan and existing agreements for following up the S ubjects enrolled 
in the clinical investigation;  
2. the principal Investigator  or authorized designee shall promptly inform the enrolled S ubjects 
at his/her investigation site, if appropriat e; 
3. the Sponsor shall arrange, and each site shall cooperate, to remove all investigational 
devices from investigational sites, and  
4. the database from the clinical T rial at the time of termination shall be locked and made 
available for inspection by regulato ry authorities or publication at a later date.  
Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent from Mainstay Medical  and are not to be used in 
any unauthoriz ed way. 
Page 76 of 84 Document Number 950057, Rev. E  25-MAR -2017 
Table 5: Study Completion Plan 
Time of Completion  After Subject  reaches final study visit  If study closed before Subject  
reaches final study visit . . .  If Subject  ends participation 
before final study visit . . .  
Note: All days are calendar days  ReActiv8  
PMA 
Approval  Decision to not 
pursue PMA 
Approval  PMA Approval 
not Granted  Study closed for 
safety reasons  Study closed for 
other reasons  Subject 
withdrawal  Subject lost to 
follow -up 
Site must notify S ubjects of the 
study completion plan within 45 days  45 days  45 days  45 days  45 days  n/a 45 days  
Will Sponsor provide ongoing 
support?  Yes No No No No No No 
IPG to be turned OFF (disabled)?  No No* No* Yes No* No No 
Will external devices be collected?  No No* No* Yes No* No No 
Explant required?  No No No No* No No No 
Will Sponsor pay for explant 
procedure if needed?  No Yes, for up to 
6 months  Yes, for up to 
6 months  Yes, for up to 6 
months  Yes, for up to 6 
months  Yes, for up to 
6 months  Yes, for up to 
6 months  
What other surgical costs will 
Sponsor pay for?  None  None  None  None  None  None  None  
Sponsor will pay for what type of 
clinic visits  None  One visit to  
1. inform of 
completion  
2. Turn off IPG  
3. collect 
externals  One visit to  
1. inform of 
completion  
2. Turn off IPG  
3. collect 
externals  One visit to  
1. inform of 
completion  
2. Turn off IPG  
3. collect 
externals  One visit to  
1. inform of 
completion  
2. Turn off IPG  
3. collect 
externals  One visit to  
1. inform of 
completion  
2. Turn off IPG  
3. collect 
externals  One visit to  
1. inform of 
completion  
2. Turn off IPG  
3. collect 
externals  
How should symptoms related to 
the device be reported?  Submit 
Complaint  Submit 
Complaint  Submit 
Complaint  Submit 
Complaint  Submit 
Complaint  Submit 
Complaint  Submit 
Complaint  
* Subject and Investigator to discuss  
 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 77 of 84 Document Number 950057, Rev. E 25-MAR -2017 
11. Administrative Data  
11.1.  Name and A ddress of the Sponsor  
MML US Inc.  
6601 Shingle Creek Parkway  
Brooklyn Center , MN 554 30 
MML US Inc. is a subsidiary of  
Mainstay Medic al Limited  
Clonmel House 
Swords,  K67F2K3  
County Dublin,  
Ireland  
Sponsor’s Contact:  
Ms. Diane Burnside  
Vice President Clinical Affairs  
diane.burnside@mainstay -medical.com  
Office: +1 763 270 -5303  
Mobile  +1 (763) 772 -7637 
11.2.  Investigators  
Each Investigational Site shall have a Site Principal Investigator. Subject to Sponsor approval, a 
Site Principal Investigator shall delegate some or all of the Subject  interaction and data 
collection to one or more S ub-investigators.  
The overall Study Principal Investigator is:  
Chris Gilligan  MD MBA  
Chief, Division of Pain Medicine  
Department of Anesthesia, Critical Care and Pain Medicine 
Brigham Pain Center  
Boylston Street, MA  
Dr. Gilligan was also Chairman of the DMC for the European Feasibility Study and the 
Chairman of the DMC for the ReActiv8- A Trial.  
11.3.  Data Monitoring Committee  
The list of mem bers, affiliations and roles and responsibilities of the DMC will be described in 
the DMC Charter, which will be stored as a part of the Trial Master File.  
11.4.  Adjudication Committee  
The list of members, affiliations and roles and responsibilities of the Adjudication Committee will 
be described in a Charter, which will be stored as a part of the Trial Master File.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 78 of 84 Document Number 950057, Rev. E 25-MAR -2017 
11.5.  Clinical Research Organizations (CROs)  
Data collection will be performed with an electronic Case Report Form ( eCRF ). A CRO will 
manage the clinical d atabase and will be responsible for randomization. The Sponsor will 
determine the data monitoring staff using the Sponsor’s and the CRO’s personnel. Subsidiary 
CROs may be used in certain countries.  
11.6.  Statements of Compliance  
This clinical investigation shal l be conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki.  
This clinical investigation shall be conducted compliance with FDA regulations, ISO 14155 and 
any regional or national regulations, as appropriate. 
The clinical investigation shall not begin until the required approval or favorable opinion from the 
FDA, IRB (or Ethics Committee), and any other regulatory body as appropriate and necessary in 
other countries . 
Any additional requirements imposed by t he IRB, Ethics Committee , FDA or Competent 
Authority  shall be followed, if appropriate.  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 79 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Appendix 1: Acronyms and Definitions  
AE Adverse Event -  any undesirable clinical occurrence that affects the health or safety 
of the Subject   
ALBP Axial Low Back Pain 
AMI Arthrogenic Muscle Inhibition – the physiological mechanism by which pain in a 
skeletal joint can inhibit activation of the muscles that surround or stabilize that joint  
BMI Body Mass Index  
CGI-I Clinical Global Impression –  Global Improvement  
CIP Clinical Investigation Plan (this document). A document that state(s) the rationale, 
objectives, design and proposed analysis, methodology, monit oring, conduct and 
record -keeping of the clinical investigation.  
NOTE  The term “protocol” is synonymous with “CIP”. However, protocol has many 
different meanings, some not related to clinical investigation, and these can 
differ from country to country. Therefore, the term CIP is used in ISO  14155.  
CLBP  Chronic Low Back Pain 
CRF Case Report Form(s) -  set of printed, optical or electronic documents for each Subject  
on which information to be reported to the Sponsor  is recorded, as required by the 
CIP ( ISO 14155)  
CRO  Contract Research Organization - person or organization contracted by the Sponsor  
to perform one or more of the Sponsor 's clinical investigation -related duties and 
functions ( ISO 14155)  
CV Curriculum vitae  
Deviation  instance(s) of failure to follow, intentionally or unintentionally, the requirements of the 
CIP ( ISO 14155).  
DD Device Deficiency. An inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety or performance.  
DMC Data Monitoring Committee - independent committee that may be established by the 
Sponsor  to assess, at intervals, the progress of the clinical investigation, the safety 
data or the critical performance endpoints and to recommend the Sponsor  whether to 
continue, suspend, modify, or stop the clinical investigation ( ISO 14155 ) 
DRG  Dorsal Root Ganglion – is a cluster of nerve cell bodies located in the posterior region 
of the various vertebrae along the spine. It is adjacent to the dorsal nerve root, which 
exists as part of a pair of nerve r oots exiting at each level of the spine.  
EC Ethics Committee - independent body whose responsibility it is to review clinical 
investigations in order to protect the rights, safety and well -being of human Subjects 
participating in a clinical investigation ( ISO 14155 - NOTE For the purposes of 
ISO 14155, “ethics committee” is synonymous with “research ethics committee”, 
“independent ethics committee” or “institutional review board”. The regulatory 
requirements pertaining to ethics committees or similar instit utions vary by country or 
region.)  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
EMG  Electromyogram  
EQ-5D European Quality of Life Assessment  
FDA Food and Drug Administration 
HCP  Health Care Personnel  
IB Investigator’s Brochure - compilation of the current clinical and non -clinical information 
on the investigational medical device(s), relevant to the clinical investigation 
(ISO 14155 ) 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 80 of 84 Document Number 950057, Rev. E 25-MAR -2017 
ICMJE  International Committee of Medical Journal Editors  
IFU Instructions for Use  
IPG Implantable Pulse Generator  
IRB Institutional Review Board (equivalent to Ethics Committee)  
Labeling  Per 21 CFR Part 801, 21 CFR Part 812, and 21 CFR Part 820, Section 201(m) defines 
‘labeling’ as: ‘all labels and other written, printed, or graphic matter (1) upon any artic le 
or any of its containers or wrappers, or (2) accompanying such article' at any time 
while a device is held for sale after shipment or delivery for shipment in interstate 
commerce. ’ Labeling thus includes package labeling and accompanying manuals.  
Malfunction   failure of an investigational medical device to perform in accordance with its intended 
purpose when used in accordance with the instructions for use or CIP ( ISO 14155)  
MF Multifidus muscle of the lumbar spine (see also LM)  
Monitoring  Act of overseeing the progress of a clinical investigation and to ensure that it is 
conducted, recorded, and reported in accordance with the CIP, written procedures, 
ISO 14155, and the applicable regulatory requirements ( ISO 14155 ) 
NRS  Numerical Rating Scale  
NSLBP  Non-Specific Low Back Pain 
NSAID  Non-Steroid Anti -Inflammatory. A class of drugs, sometimes used for low back pain.  
ODI Oswestry Disability Index  
OTC  Over the Counter –  refers to non- prescription medications  
PI Principal Investigator. A qualified physician who takes overall responsibility for 
conduct of the trial according to the protocol an d regulations.  
PMA Pre-Market Approval  
PMCF  Post-Market Clinical Follow Up  
PRO  Patient Reported Outcome  
QOL  Quality of Life  
Re-implant surgery  A surgical procedure in which a new device is implanted to replace a device 
removed in a prior surgical procedure.  
Removal Surgery  A surgical procedure in which at least one of either the leads or IPG is 
removed and not replaced with a device of the same type during the sa me surgical 
procedure  
Replacement Surgery   A surgical procedure that involves r emoval of one device component and 
implantation of a new device component of same type, e.g. lead, during a single 
surgical procedure  
Revision Surgery  Surgical procedure perform ed on a currently implanted device, e.g. 
repositioning a dislodged lead  
SAE Serious Adverse Event. an adverse event that led to death, or led to serious 
deterioration in the health of the Subject , that either resulted in:  
1. a life -threatening illness or injury, or  
2. a permanent impairment of a body structure or a body function, or  
3. in-patient or prolonged hospitalization,  
4. congenital anomaly/birth defect, or  
5. medical or surgical intervention to prevent life- threatening illness or injury or 
permanent impairment to a body structure or a body function.  
Note:  Planned hospitalization for a pre -existing condition or a procedure required by 
the protocol (e.g., the index implant procedure, or device replacement due to 
normal battery depletion), without serious deterioration in health, is not 
considered a serious adverse event.  
SAP Statistical Analysis Plan  
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 81 of 84 Document Number 950057, Rev. E 25-MAR -2017 
SCS Spinal Cord Stimulator  
SGIC  Subject Global Impression of Change 
Site PI  Site Principal Investigator -  qualified person responsibl e for conducting the clinical 
investigation at an investigation site ( ISO 14155 ) 
Sponsor  Individual or organization taking responsibility and liability for the initiation or 
implementation of a clinical investigation. F or this Trial, it is Mainstay Medical  Limited.  
Subject  An individual who participates in a clinical investigation. A Subject  can be either a 
healthy volunteer or a patient. ( ISO 14155)  
TENS  Transcutaneous Electrical Nerve Stimulation  
TSQ Treatment Satisfaction Questionnaire  
UADE  Unanticipated Adverse Device Effect . Any serious adverse effect on health or safety 
or any life- threatening problem or death caused by or associated with, a device, if 
that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational plan or application, or any other 
unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of S ubjects.  
VAS Visual -Analogue Scale 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 82 of 84 Document Number 950057, Rev. E 25-MAR -2017 
Appendix 2: Bibliography  
1. Deckers, K. et al.  Chronic Low Back Pain: Restoration of Dynamic Stability. Neuromodulation  18, 478– 86 (2015).  
2. Airaksinen, O. et al.  Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur. Spine 
J. 15 Suppl 2,  S192- 300 (2006).  
3. Woolf, A. D. & Pfleger, B. Burden of major musculoskeletal conditions. Bull. World Health Organ.  81, 646–56 (2003).  
4. Deyo, R. a et al.  Report of the NIH Task Force on Research Standards for Chronic Low Back Pain. Spine J.  14, 1375– 91 
(2014).  
5. Woolf, A. D. & Pfleger, B. Burden of major musculoskeletal conditions. Bull. World Health Organ.  81, 646–56 (2003).  
6. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived 
with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990- 2013: a systematic analysis for the 
Global Burden of Diseas e Study 2013. Lancet (London, England)  6736,  1990– 2013 (2015).  
7. Kent, P. M. & Keating, J. L. The epidemiology of low back pain in primary care. Chiropr. Osteopat.  13, 13 (2005).  
8. Strine, T. W. & Hootman, J. M. US national prevalence and correlates of l ow back and neck pain among adults. Arthritis 
Rheum.  57, 656– 65 (2007).  
9. Deyo, R. A., Mirza, S. K. & Martin, B. I. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. 
Spine (Phila. Pa. 1976).  31, 2724– 7 (2006).  
10. Freburger , J. K. et al.  The rising prevalence of chronic low back pain. Arch. Intern. Med.  169, 251– 8 (2009).  
11. Pengel, L. H. M., Herbert, R. D., Maher, C. G. & Refshauge, K. M. Acute low back pain: systematic review of its prognosis. 
BMJ 327, 323 (2003).  
12. Andersson, G. B. Epidemiological features of chronic low -back pain. Lancet  354, 581– 585 (1999).  
13. Dagenais, S., Caro, J. & Haldeman, S. A systematic review of low back pain cost of illness studies in the United States and 
internationally . Spine J.  8, 8–20 (2008).  
14. Wasiak, R., Kim, J. & Pransky, G. Work Disability and Costs Caused by Recurrence of Low Back Pain: Longer and More 
Costly Than in First Episodes. Spine (Phila. Pa. 1976).  31, 219– 225 (2006).  
15. Deyo, R. A. & Weinstein, J. N.  Low Back Pain. NEJM  344, 363– 370 (2001).  
16. Savigny, P. et al.  Low back pain : early management of persistent non- specific low back pain. Full guideline (NICE) . 
Primary Care  (2009).  
17. Chou, R. et al.  Diagnosis and treatment of low back pain: a joint cl inical practice guideline from the American College of 
Physicians and the American Pain Society. Ann. Intern. Med.  147, 478– 91 (2007).  
18. van Tulder, M. W., Malmivaara, A. V, Esmail, R. & Koes, B. W. Exercise therapy for low back pain. Spine (Phila. Pa. 1976).  
25, 2784– 2796 (2000).  
19. Hayden, J. A., van Tulder, M. W., Malmivaara, A. V & Koes, B. W. Exercise therapy for treatment of non- specific low back 
pain. Cochrane Database Syst. Rev.  3, CD000335 (2005).  
20. Hayden, J. A., van Tulder, M. W., Malmivaara, A. V & Koes, B. W. Meta -analysis: exercise therapy for nonspecific low back 
pain. Ann. Intern. Med.  142, 765– 75 (2005).  
21. Bogduk, N. Management of chronic low back pain. Med. J. Aust.  180, (2004).  
22. Mayer, J., Mooney, V. & Dagenais, S. Evidence- informed management of chronic low back pain with lumbar extensor 
strengthening exercises. Spine J.  8, 96–113 (2008).  
23. Pradhan, B. B. Evidence- informed management of chronic low back pain with watchful waiti ng. Spine J.  8, 253– 7 (2008).  
24. Gay, R. E. & Brault, J. S. Evidence- informed management of chronic low back pain with traction therapy. Spine J.  8, 234–
42 (2008).  
25. May, S. & Donelson, R. Evidence- informed management of chronic low back pain with the McKenzie method. Spine J.  8, 
134– 41 (2008).  
26. Deyo, R. A., Walsh, N. E., Martin, D. C., Schoenfeld, L. S. & Ramamurthy, S. A controlled trial of transcutaneous electric al 
nerve stimulation (TENS) and exercise for chronic low back pain. N. Engl. J. Med.  322, 1627– 34 (1990).  
27. Orrock, P. J. & Myers, S. P. Osteopathic intervention in chronic non- specific low back pain: a systematic review. BMC 
Musculoskelet. Disord.  14, 129 (2013).  
28. Poitras, S. & Brosseau, L. Evidence- informed management of chronic low back pain with transcutaneous electrical nerve 
stimulation, interferential current, electrical muscle stimulation, ultrasound, and thermotherapy. Spine J.  8, 226– 33 (2008).  
29. Standaert, C. J., Weinstein, S. M. & Rumpeltes, J. Evidence- informed management of chronic low back pain with lumbar 
stabilization exercises. Spine J.  8, 114– 20 (2008).  
30. Young,  a. Current issues in arthrogenous inhibition. Ann. Rheum. Dis.  52, 829– 34 (1993).  
31. Stevens, V. K. et al.  The influence of specific training on trunk muscle recruitment patterns in healthy subjects during 
stabilization exercises. Man. Ther.  12, 271– 279 (2006).  
32. Macdonald, D. A., Moseley, G. L. & Hodges, P. W. Why do some patients keep hurting their back? Evidence of ongoing 
back muscle dysfunction during remission from recurrent back pain. Pain 142, 183– 8 (2009).  
33. Kiesel, K. B. et al.  Experimentally induced pain alters the EMG activity of the lumbar multifidus in asymptomatic subjects. 
Man. Ther.  (2012). doi:10.1016/j.math.2012.01.008 
34. Wallwork, T. L., Stanton, W. R., Freke, M. & Hides, J. A. The effect of chronic low back pain on size and contraction of the 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 83 of 84 Document Number 950057, Rev. E 25-MAR -2017 
lumbar multifidus muscle. Man. Ther.  14, 496– 500 (2009).  
35. Kiesel, K. B., Uhl, T. L., Underwood, F. B., Rodd, D. W. & Nitz, A. J. Measurement of lumbar multifidus muscle contraction 
with rehabilitative ultrasound imaging. Man. Ther.  12, 161– 6 (2007).  
36. Lee, S. et al.  Relationship Between Low Back Pain and Lumbar Multifidus Size at Different Postures. Spine (Phila. Pa. 
1976).  31, 2258– 2262 (2006).  
37. Stevens -Lapsley, J. E., Balter, J. E., Wolfe, P., Eckhoff, D. G. & Kohrt, W. M. Early neuromuscular electrical stimulation to 
improve quadriceps muscle strength after total knee arthroplasty: a randomized controlled trial. Phys. Ther.  92, 210– 26 
(2012).  
38. Avramidis, K., Strike, P. W., Taylor, P. N. & Swain, I. D. Effectiveness of electric stimulation of the vastus medialis muscl e 
in the rehabilitation of patients after total knee arthroplasty. Arch. Phys. Med. Rehabil.  84, 1850– 3 (2003).  
39. Stevens, J. E ., Mizner, R. L. & Snyder -Mackler, L. Neuromuscular electrical stimulation for quadriceps muscle 
strengthening after bilateral total knee arthroplasty: a case series. J. Orthop. Sports Phys. Ther.  34, 21–9 (2004).  
40. Walls, R. J., McHugh, G., Moyna, N. M.  & O’Byrne, J. Efficacy and Compliance of a Quadriceps Femoris Neuromuscular 
Stimulation Program in Subjects with Severe Knee Osteoarthritis. in European Orthopaedics Research Society  (2008).  
41. Beneck, G. J. & Kulig, K. Multifidus atrophy is localized and bilateral in active persons with chronic unilateral low back pain. 
Arch. Phys. Med. Rehabil.  93, 300– 6 (2012).  
42. D’hooge, R. et al.  Lumbar muscle dysfunction during remission of unilateral recurrent nonspecific low -back pain: evaluation 
with muscle functional MRI. Clin. J. Pain  29, 187– 94 (2013).  
43. Dickx, N., Cagnie, B., Parlevliet, T., Lavens,  a & Danneels, L. A. The effect of unilateral muscle pain on recruitment of the 
lumbar multifidus during automatic contraction. An experimental pain study. Man.  Ther.  15, 364– 9 (2010).  
44. Dworkin, R. H. et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT 
recommendations. J. Pain  9, 105– 21 (2008).  
45. Turk, D. C. et al.  Developing patient -reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 
125, 208– 15 (2006).  
46. Dworkin, R. H. et al.  Research design considerations for confirmatory chronic pain clinical trials: IMMPACT 
recommendations. Pain 149, 177– 93 (2010).  
47. Hawker, G. A., Mian, S., Kendzerska, T. & French, M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), 
Numer ic Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short -Form McGill Pain Questionnaire (SF -
MPQ), Chronic Pain Grade Scale (CPGS), Short Form -36 Bodily Pain Scale (SF. Arthritis Care Res.  63, 240– 252 (2011).  
48. Fairbank, J. & Pynsent, P . B. The Oswestry Disability Index. Spine (Phila. Pa. 1976).  25, 2940– 52; discussion 2952 (2000).  
49. Lamb, S. E. et al.  A multicentred randomised controlled trial of a primary care- based cognitive behavioural programme for 
low back pain. the back skills t raining (BeST) trial. Health Technol. Assess. (Rockv).  14, 1–281 (2010).  
50. Vibe Fersum, K., O’Sullivan, P. B., Skouen, J. S., Smith, A. & Kvåle, A. Efficacy of classification- based cognitive functional 
therapy in patients with non- specific chronic low ba ck pain: a randomized controlled trial. Eur. J. Pain  17, 916– 28 (2013).  
51. Farrar, J. T., Dworkin, R. H. & Max, M. B. Use of the cumulative proportion of responders analysis graph to present pain 
data over a range of cut -off points: making clinical trial data more understandable. J. Pain Symptom Manage.  31, 369– 77 
(2006).  
52. Negrini, S. et al.  2011 SOSORT guidelines: Orthopaedic and Rehabilitation treatment of idiopathic scoliosis during growth. 
Scoliosis  7, 3 (2012).  
53. Lovibond, P. F. & Lovibond, S. H. The structure of negative emotional states: Comparison of the depression anxiety stress 
scales (DASS) with the Beck Depression and Anxiety Inventories. Behav. Res. Ther.  33, 335– 343 (1995).  
54. Lovibond SH, L. P. Manual for the Depression Anxiety Stress Scales . (The Psychology Foundation of New South Wales 
Inc, University of New South Wales, 1995).  
55. Hicks, G. E., Fritz, J. M., Delitto, A. & McGill, S. M. Preliminary development of a clinical prediction rule for determining 
which patients with low back pain will respond to a stabilization exercise program. Arch. Phys. Med. Rehabil.  86, 1753– 62 
(2005).  
56. Hicks, G. E., Fritz, J. M., Delitto, A. & Mishock, J. Interrater Reliability of Clinical Examination Measures for Identificat ion of 
Lumbar Segmental Instability. Arch. Phys. Med. Rehabil.  84, 1858– 1864 (2003).  
57. Hebert, J. J., Koppenhaver, S. L., Magel, J. S. & Fritz, J. M. The relationship of transversus abdominis and lumbar 
multifidus activation and prognostic factors for clinical success with a stabilization exercise program: a cross -sectional 
study. Arch. Phys . Med. Rehabil.  91, 78–85 (2010).  
58. May, S. & Johnson, R. Stabilisation exercises for low back pain: a systematic review. Physiotherapy  94, 179– 189 (2008).  
59. Hägg, O., Fritzell, P. & Nordwall,  a. The clinical importance of changes in outcome scores aft er treatment for chronic low 
back pain. Eur. Spine J.  12, 12–20 (2003).  
60. Ostelo, R. W. et al.  Interpreting change scores for pain and functional status in low back pain: towards international 
consensus regarding minimal important change. Spine (Phila. P a. 1976).  33, 90–4 (2008).  
61. Garratt, A., Schmidt, L., Mackintosh, A. & Fitzpatrick, R. Quality of life measurement: bibliographic study of patient 
assessed health outcome measures. BMJ  324, 1417 (2002).  
62. Solberg, T. K., Olsen, J. -A., Ingebrigtsen, T. , Hofoss, D. & Nygaard, O. P. Health- related quality of life assessment by the 
EuroQol -5D can provide cost -utility data in the field of low -back surgery. Eur. Spine J.  14, 1000– 7 (2005).  
63. Herdman, M. et al.  Development and preliminary testing of the new  five-level version of EQ -5D (EQ -5D-5L). Qual. Life Res.  
20, 1727– 36 (2011).  
64. Janssen, M. F. et al.  Measurement properties of the EQ -5D-5L compared to the EQ -5D-3L across eight patient groups: a 
 Clinical Investigation Plan –  ReActiv8- B 
The contents of this document are confidential and are not to be reproduced or made available to third parti es without prior consent 
from Mainstay Medical  and are not to be used in any unauthoriz ed way.  
Page 84 of 84 Document Number 950057, Rev. E 25-MAR -2017 
multi -country study. Qual. Life Res.  22, 1717– 27 (2013).  
65. Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L. & Poole, R. M. Clinical importance of changes in chronic pain 
intensity measured on an 11- point numerical pain rating scale. Pain  94, 149– 58 (2001).  
66. McCarney, R. et al.  The Hawthorne Effect: a randomised, controlled trial. BMC Med. Res. Methodol.  7, 30 (2007).  
67. Bang, H., Flaherty, S. P., Kolahi, J. & Park, J. Blinding assessment in clinical trials: A review of statistical methods and a 
proposal of blinding assessment protocol. Clin. Res. Regul. Aff.  27, 42–51 (2010).  
68. Don, A. S. & Carragee, E. A brief overview of evidence- informed management of chronic low back pain with surgery. Spine 
J. 8, 258– 65 (2007).  
69. Chou, R. et al.  Interventional therapies, surgery, and i nterdisciplinary rehabilitation for low back pain: an evidence- based 
clinical practice guideline from the American Pain Society. Spine (Phila. Pa. 1976).  34, 1066– 77 (2009).  
 